Treatment agent, waste liquid treatment implement, and downstream-side waste liquid treatment implement

MYPI2025002315A0Undetermined Publication Date: 2024-04-28EXCELSIOR
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025002315
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-10-28
Filing Date
2023-08-03
Publication Date
2024-04-28

AI Technical Summary

Technical Problem

In situations where flush toilets are not available, such as emergency evacuation areas, areas with poor infrastructure, and medical facilities like operating and endoscopy rooms, there is a challenge in effectively managing and disposing of waste liquids containing excrement, blood, and body fluids, particularly due to the risk of odors from indole and skatole and the potential for clogging in waste liquid treatment systems.

Method used

A processing agent comprising slaked lime and pepper is used to treat waste liquids, which reduces odors by converting the liquids into a solid form, preventing scattering and clogging, and includes a waste liquid processing tool with a partition member to manage fluid flow and prevent blockages in downstream systems.

Benefits of technology

The solution effectively reduces malodorous compounds like indole and skatole, ensures safe and sanitary disposal of waste liquids, and prevents clogging in treatment systems, making it suitable for areas without proper infrastructure and medical facilities.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025002315_DRAWING_001
    Figure PI2025002315_DRAWING_001
  • Figure PI2025002315_DRAWING_002
    Figure PI2025002315_DRAWING_002
  • Figure PI2025002315_DRAWING_003
    Figure PI2025002315_DRAWING_003
Patent Text Reader

Abstract

Provided is a novel treatment agent that can reduce foul odors including indole and skatole, and also provided is a novel treatment agent that can be applied to at least one of operation rooms, endoscopy rooms, emergency evacuation sites where flushing toilets cannot be used, infrastructure-lacking regions such as mountains and beaches, living rooms for people who require nursing care and cannot use a toilet by themselves, and the like. The treatment agent is a treatment agent for treating waste liquid and contains slaked lime and pepper. Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

Treatment agent, waste liquid treatment tool, and downstream waste liquid treatment tool

[0001] The present invention relates to a processing agent, a waste liquid processing device, and a downstream waste liquid processing device.

[0002] Proper disposal of excrement is important for maintaining a hygienic and comfortable environment, but this can be difficult in a variety of situations and places, such as evacuation sites where flush toilets cannot be used during emergencies and disasters, areas without infrastructure such as mountainous or coastal areas, rooms of people requiring care who cannot go to the toilet on their own, and hospital rooms such as operating rooms and endoscopy rooms.

[0003] For example, in an endoscopy room, the endoscope is divided into upper examinations, which are performed through the mouth or nose to examine the stomach, etc., and lower examinations, which are performed through the anus to examine the rectum, large intestine, and small intestine. Both upper and lower examinations involve suction of bodily fluids, and in some cases washing with water during the examination, so waste liquid containing excrement, blood, and bodily fluids is discharged. The waste liquid containing bodily fluids generated in this way is sent for waste disposal.

[0004] Patent Document 1 discloses a configuration in which a treatment agent composed entirely or mainly of a high molecular weight absorbent polymer is placed inside a collection container to absorb waste liquid that flows down into the collection container through a waste liquid inlet pipe. As a result, the waste liquid collected by suction into the sealed collection container is supplied with a treatment agent that has been placed inside the collection container in advance, and is gradually gelled. As a result, there is no risk of the collected waste liquid scattering outside the collection container, and the system is said to be highly safe.

[0005] Japanese Patent Application Publication No. 02-157083

[0006] Although Patent Document 1 only mentions the problem of wastewater treatment, there is also the problem of foul odors from excrement, particularly from indole and skatole, which are very unpleasant and cause headaches for medical professionals.

[0007] Therefore, an object of the present invention is to provide a novel treatment agent that can reduce malodors containing indole and skatole, and further to provide a novel treatment agent that can be used for at least one of wastewater treatment in operating rooms, endoscopy rooms, evacuation sites where flush toilets cannot be used, areas without infrastructure such as mountainous or seaside areas, and rooms of people requiring care who cannot go to the toilet by themselves.

[0008] One aspect of the present invention is a treatment agent comprising hydrated lime and pepper.

[0009] According to one aspect of the present invention, a novel treating agent is provided that can reduce malodors containing indole and skatole, and thus can be provided that is applicable to at least one of wastewater treatment in operating rooms, endoscopy rooms, evacuation sites where flush toilets cannot be used, areas without infrastructure such as mountainous or coastal areas, rooms of people requiring care who cannot go to the toilet on their own, etc. Furthermore, such a treating agent can also be used to treat excrement, blood, vomit, or body fluids discharged from humans or animals, and organic sludge such as food waste.

[0010] 1 is a color photograph showing the inhibitory effect of sample A on the growth of spore-forming bacteria.

[0033] FIG. 1 is a schematic perspective view showing a waste liquid treatment device and a downstream-side waste liquid treatment device according to an embodiment.

[0034] FIG. 2 is a front view of FIG. 2.

[0035] FIG. 3 is an exploded perspective view showing the configuration of the waste liquid treatment device according to FIG. 2.

[0036] FIG. 4 is a cross-sectional view along the height direction showing the interior of the waste liquid treatment device according to FIG. 3.

[0037] FIG. 5 is a perspective view showing the lid and partition member constituting the waste liquid treatment device according to FIG. 3.

[0038] FIG. 6 is a perspective view showing the lid and partition member cut at a position different from that in FIG. 6.

[0039] FIG. 7 is an exploded perspective view showing the configuration of the partition member.

[0039] FIG. 8 is a plan view showing the partition member.

[0039] FIG. 9 is an exploded perspective view showing the configuration of the downstream-side waste liquid treatment device shown in FIG. 2.

[0039] FIG. 10 is a cross-sectional view along the height direction showing the interior of the downstream-side waste liquid treatment device.

[0039] FIG. 11 is an enlarged view of FIG. 11 showing the lid, connecting member, mounting member, and displacement member when gas or the like used for suction flows through the interior of the mounting member.

[0039] FIG. 12 is an enlarged view of FIG. 13 showing a state in which the position of the displacement member in FIG. 13 is different from that in FIG. 13.

[0039] FIG. 13 is an exploded perspective view of a waste liquid treatment device showing a modified example of FIG. 4. Fig. 17 is an exploded perspective view showing a downstream waste liquid processing device according to a modified example of Fig. 10. Fig. 18 is a perspective view showing a partition member according to a modified example. Fig. 19 is an exploded perspective view of Fig. 17. Fig. 20 is a plan view of Fig. 21. Fig. 22 is a perspective view showing a partition member according to a modified example. Fig. 23 is a view showing a modified example of Fig. 13. Fig. 24 is a view showing a modified example of Fig. 14. Fig. 25 is a perspective view showing a modified example of Fig. 1. Fig. 26 is an exploded perspective view showing a capture assembly attached to a waste liquid processing device according to a modified example. Fig. 27 is a view showing the inside of the capture assembly.

[0011] First Invention First, the first invention will be described.

[0012] In this specification, the term "X to Y" indicating a range means "X or more and Y or less." When multiple "X to Y" are listed, for example, when "X1 to Y1 or X2 to Y2" is listed, the disclosure of each numerical value as an upper limit, the disclosure of each numerical value as a lower limit, and combinations of these upper and lower limits are all disclosed (i.e., legal basis for correction). Specifically, corrections to X1 or more, corrections to Y2 or less, corrections to X1 or less, corrections to Y2 or more, corrections between X1 and X2, and corrections between X1 and Y2 must all be considered legal. Unless otherwise specified, operations and measurements of physical properties are performed at room temperature (20-25°C) and a relative humidity of 40-50% RH. Unless otherwise specified, % means % by mass.

[0013] One aspect of the present invention is a treatment agent for treating wastewater, the treatment agent comprising slaked lime and pepper. This treatment agent can reduce malodors containing indole and skatole, and is therefore applicable to treating wastewater in at least one of the following locations where this problem is prevalent: operating rooms, endoscopy rooms, evacuation sites where flush toilets are unavailable, areas with poor infrastructure such as mountainous or coastal areas, and rooms of people requiring care who cannot go to the toilet on their own.

[0014] In one embodiment of the present invention, the waste liquid is excrement, blood, vomit, or bodily fluids discharged from a human or animal. In one embodiment of the present invention, the waste liquid is fluid (excrement, blood, bodily fluids, etc.) discharged from a patient during a medical procedure such as an endoscopic examination (upper examination, lower examination). In one embodiment of the present invention, the waste liquid may be human excrement (feces and / or urine) (in the case of only feces, it may contain liquids such as water).

[0015] In one embodiment of the present invention, the waste liquid contains at least one malodorous component selected from the group consisting of n-butyric acid, n-valeric acid, isovaleric acid, indole, and skatole. In one embodiment of the present invention, the waste liquid contains at least one of indole and skatole as a malodorous component. The treating agent of the present invention is effective not only for deodorizing (including reducing odors of) fatty acids such as n-butyric acid, n-valeric acid, and isovaleric acid, but also for deodorizing (including reducing odors of) at least one of indole and skatole in particular. In one embodiment of the present invention, the treating agent is a treating agent for deodorizing at least one of indole and skatole.

[0016] (Slaked Lime) The treating agent of one embodiment of the present invention contains slaked lime. In one embodiment of the present invention, the content (mass%) of slaked lime in the treating agent is 0.1 mass% or more, 0.5 mass% or more, 1 mass% or more, 2 mass% or more, 3 mass% or more, 5 mass% or more, 6 mass% or more, 7 mass% or more, 8 mass% or more, 9 mass% or more, 10 mass% or more, 12 mass% or more, 15 mass% or more, 17 mass% or more, 20 mass% or more, or 30 mass% or more. In one embodiment of the present invention, the content (mass%) of slaked lime in the treatment agent is 70% by mass or less, 60% by mass or less, 50% by mass or less, 40% by mass or less, 35% by mass or less, 30% by mass or less, 28% by mass or less, 25% by mass or less, 20% by mass or less, 15% by mass or less, 14% by mass or less, 13% by mass or less, 10% by mass or less, 9% by mass or less, 8% by mass or less, 7% by mass or less, 6% by mass or less, 5% by mass or less, 4% by mass or less, or 3% by mass or less. In one embodiment of the present invention, the content (mass%) of slaked lime in the treatment agent is 0.1 to 40% by mass, 0.5 to 35% by mass, 1 to 30% by mass, 3 to 28% by mass, 5 to 25% by mass, or 7 to 15% by mass.

[0017] In one embodiment of the present invention, the average particle size of the slaked lime is, for example, 10 μm or more, or 50 μm or more. In one embodiment of the present invention, the average particle size of the slaked lime is, for example, 1000 μm or less, 500 μm or less, or 300 μm or less. Unless otherwise specified, the term "average particle size" used in this specification refers to the arithmetic mean value obtained by arbitrarily selecting a statistically reliable number of particles (e.g., 100, 200, 300, or 1000 particles), measuring the longest particle diameter for each particle under a microscope, and then averaging the measured values. To obtain the desired average particle size, the slaked lime may be sieved as appropriate. In one embodiment of the present invention, the slaked lime is preferably prepared by purchasing a commercially available product, such as that from Ube Material Industries, Ltd.

[0018] (Pepper) A treatment agent according to one embodiment of the present invention includes pepper. Pepper is a fruit that grows on the Piper nigrum pepper plant. In one embodiment of the present invention, the pepper may be any of black pepper, white pepper, green pepper, and pink pepper.

[0019] In one embodiment of the invention, the pepper is not in the form of a piperine extract.

[0020] In one embodiment of the present invention, the average particle size of the pepper is, for example, 10 μm or more, or 50 μm or more. In one embodiment of the present invention, the average particle size of the pepper is, for example, 1000 μm or less, 500 μm or less, or 300 μm or less.

[0021] In one embodiment of the present invention, the pepper content (mass%) in the treatment agent is 0.05% by mass or more, 0.1% by mass or more, 0.5% by mass or more, 1% by mass or more, 1.5% by mass or more, 1.6% by mass or more, 1.7% by mass or more, 1.8% by mass or more, 2% by mass or more, 2.5% by mass or more, 3% by mass or more, 3.2% by mass or more, 3.5% by mass or more, 3.8% by mass or more, 4% by mass or more, 5% by mass or more, 6% by mass or more, 7% by mass or more, 8% by mass or more, 9% by mass or more, 10% by mass or more, 12% by mass or more, 14% by mass or more, 16% by mass or more, 18% by mass or more, or 20% by mass or more. According to one embodiment of the present invention, the pepper content (mass%) in the treatment agent is 55% by mass or less, 45% by mass or less, 40% by mass or less, 30% by mass or less, 25% by mass or less, 20% by mass or less, 15% by mass or less, 10% by mass or less, 9% by mass or less, 8% by mass or less, 7% by mass or less, 6% by mass or less, 5.5% by mass or less, 5% by mass or less, 4% by mass or less, 3.8% by mass or less, 3.5% by mass or less, or 3% by mass or less.

[0022] According to one embodiment of the present invention, the pepper content (mass%) in the treatment agent is 0.05 to 30% by mass, 0.1 to 25% by mass, 0.5 to 20% by mass, 1 to 15% by mass, 1.5 to 10% by mass, 1.6 to 9% by mass, 1.7 to 8% by mass, 1.8 to 7% by mass, 1.8 to 6% by mass, 1.8 to 5% by mass, 1.8 to 4.5% by mass, or 1.8 to 3.8% by mass.

[0023] According to one embodiment of the present invention, these content ratios (mass %) may be values ​​obtained by calculation including the binder in the treatment agent, or values ​​obtained by calculation excluding the binder from the treatment agent. Note that, similarly to the above, the content ratios (mass %) of components in the treatment agent described in this specification may be values ​​obtained by calculation including the binder in the treatment agent, or values ​​obtained by calculation excluding the binder from the treatment agent.

[0024] According to one embodiment of the present invention, the treatment agent may or may not contain a binder. The preferred range of the content ratio (mass %) of each component in the treatment agent may vary depending on whether or not a binder is used.

[0025] (Water-absorbent polymer) A treatment agent according to one embodiment of the present invention contains a water-absorbent polymer. By including a water-absorbent polymer, moisture and the like in the object to be treated are absorbed, and the treated object is more likely to solidify (become jelly-like). In this specification, the term "water-absorbent polymer (water-absorbent resin)" refers to a polymer gelling agent having a water swelling capacity (CRC) defined by ERT441.2-02 of 5 g / g or more and a water-soluble component (Ext) defined by ERT470.2-02 of 50 mass% or less.

[0026] In one embodiment of the present invention, specific examples of water-absorbent polymers include starch-based water-absorbent polymers such as starch-acrylonitrile graft polymer hydrolysates and starch-acrylic acid graft polymers; cellulose-based water-absorbent polymers such as cellulose-acrylonitrile graft polymers and cellulose-styrene sulfonic acid graft copolymers; polysaccharide-based water-absorbent polymers such as pectin; protein-based water-absorbent polymers such as collagen; polyvinyl alcohol-based water-absorbent polymers such as polyvinyl alcohol crosslinked polymers; acrylic-based water-absorbent polymers such as sodium polyacrylate crosslinked products, acrylic acid polymer partial sodium salt crosslinked products, and sodium acrylate-vinyl alcohol copolymers; maleic anhydride-based water-absorbent polymers; vinylpyrrolidone-based water-absorbent polymers; and polyether-based water-absorbent polymers such as polyethylene glycol diacrylate crosslinked polymers. These water-absorbent polymers may be used alone or in combination of two or more. Furthermore, these water-absorbent polymers may be synthesized or commercially available products may be used. Examples of commercially available products include AQUAKEEP (registered trademark) SA (manufactured by Sumitomo Seika Chemicals Co., Ltd.), AQUALIC (registered trademark) CA (manufactured by Nippon Shokubai Co., Ltd.), SANFRESH (ST-250, ST-100, ST-573), AQUAPEARL (manufactured by Sandia Polymers Co., Ltd.), HYMOSUB HS-960 (manufactured by HYMO Corporation), and EF POLYMER (manufactured by EF Polymer Private Limited).

[0027] In one embodiment of the present invention, the water-absorbing polymer may be carboxymethyl cellulose. Carboxymethyl cellulose is a cellulose derivative, and has carboxymethyl groups (—CH ) attached to some of the hydroxy groups of the gluconopyranose monomers that constitute the cellulose backbone. 2 The carboxymethyl cellulose is a thickener having a high affinity for water and forming a highly viscous gel when mixed with water. In the present invention, the thickening of the treatment agent enhances the malodor suppression effect and allows the suppression effect to be maintained.

[0028] According to one embodiment of the present invention, the average particle size of the water-absorbing polymer is 1 to 1200 μm, 50 to 1100 μm, 10 to 1000 μm, 80 to 850 μm, 100 to 600 μm, 150 to 500 μm, or 200 to 400 μm.

[0029] According to one embodiment of the present invention, the content (mass%) of the water-absorbing polymer in the treatment agent is 1% by mass or more, 5% by mass or more, 10% by mass or more, 15% by mass or more, 20% by mass or more, 25% by mass or more, 28% by mass or more, 30% by mass or more, 35% by mass or more, 40% by mass or more, 45% by mass or more, 50% by mass or more, 55% by mass or more, 60% by mass or more, or 65% by mass or more. According to one embodiment of the present invention, the content (mass%) of the water-absorbing polymer in the treatment agent is 99% by mass or less, 95% by mass or less, 90% by mass or less, 85% by mass or less, 80% by mass or less, 75% by mass or less, 70% by mass or less, 65% by mass or less, 60% by mass or less, 55% by mass or less, 50% by mass or less, 45% by mass or less, 40% by mass or less, or 35% by mass or less.

[0030] According to one embodiment of the present invention, the content (mass%) of the water-absorbing polymer in the treatment agent is 1% to 99% by mass, 5 to 95% by mass, 10 to 90% by mass, 15 to 85% by mass, 20 to 80% by mass, 25 to 75% by mass, 30 to 70% by mass, 35 to 65% by mass, 40 to 60% by mass, or 45 to 55% by mass. According to one embodiment of the present invention, the content (mass%) of the water-absorbing polymer in the treatment agent is 25 to 60% by mass.

[0031] (Zinc Oxide) According to one embodiment of the present invention, the treatment agent contains zinc oxide. Zinc oxide is an oxide of zinc represented by ZnO, and has the effect of absorbing odorous components such as ammonia and sulfides to deodorize and eliminate odors. Zinc oxide can be freely selected from commercially available products. Examples include Zinc Oxide Type I (manufactured by Hakusui Tech Co., Ltd.), Zinc Oxide Type II (manufactured by Hakusui Tech Co., Ltd.), Pazet AB, Pazet AK, and Pazet CK (all manufactured by Hakusui Tech Co., Ltd.).

[0032] According to one embodiment of the present invention, the zinc oxide content (mass%) in the treatment agent is 0.05 mass% or more, 0.1 mass% or more, 0.25 mass% or more, 0.5 mass% or more, 1 mass% or more, 1.5 mass% or more, 2 mass% or more, 2.5 mass% or more, 3 mass% or more, 3.5 mass% or more, 3.8 mass% or more, 4 mass% or more, 4.2 mass% or more, 4.4 mass% or more, 4.6 mass% or more, 4.8 mass% or more, 5 mass% or more, 5.2 mass% or more, 5.4 mass% or more, 5.6 mass% or more, 5.8 mass% or more, 6 mass% or more, 6.2 mass% or more, or 6.4 mass% or more.

[0033] According to one embodiment of the present invention, the zinc oxide content (mass %) in the treatment agent is 30 mass % or less, 25 mass % or less, 23 mass % or less, 20 mass % or less, 18 mass % or less, 15 mass % or less, 10 mass % or less, 9 mass % or less, 8 mass % or less, 7 mass % or less, 6 mass % or less, 5 mass % or less, 4 mass % or less, or 3 mass % or less.

[0034] According to one embodiment of the present invention, the zinc oxide content (mass%) in the treatment agent is 0.05 to 30 mass%, 0.1 to 25 mass%, 0.5 to 20 mass%, 1 to 15 mass%, 2 to 10 mass%, 2.5 to 8 mass%, 3 to 6 mass%, 3.5 to 5 mass%, or 3.8 to 4 mass%. According to one embodiment of the present invention, the zinc oxide content (mass%) is 2.5 to 30 mass%.

[0035] (Lignin) According to one embodiment of the present invention, the treatment agent contains lignin. Lignin is a polymeric phenolic compound involved in lignification in higher plants and is also called xylem. Lignin can exert the effects of adsorbing and decomposing ammonia and other odorous substances.

[0036] According to one embodiment of the present invention, the lignin content (mass%) in the treatment agent is 0.01% by mass or more, 0.05% by mass or more, 0.1% by mass or more, 0.5% by mass or more, 0.8% by mass or more, 1% by mass or more, 1.2% by mass or more, 1.5% by mass or more, or 1.8% by mass or more. According to one embodiment of the present invention, the lignin content (mass%) in the treatment agent is 30% by mass or less, 25% by mass or less, 20% by mass or less, 15% by mass or less, 10% by mass or less, 8% by mass or less, 6% by mass or less, 4% by mass or less, 3.5% by mass or less, 3.3% by mass or less, 3.1% by mass or less, 3.0% by mass or less, 2.8% by mass or less, 2.6% by mass or less, or 2.4% by mass or less.

[0037] According to one embodiment of the present invention, the lignin content (mass%) in the treatment agent is 0.01 to 30 mass%, 0.05 to 25 mass%, 1 to 20 mass%, 1.5 to 15 mass%, 1.5 to 10 mass%, 1.5 to 8 mass%, 1.5 to 6 mass%, 1.5 to 4 mass%, or 1.5 to 3 mass%. According to one embodiment of the present invention, the lignin content (mass%) is 1 to 3.5 mass%.

[0038] According to one embodiment of the present invention, the average particle size of the lignin is 1 to 500 μm, 5 to 300 μm, 10 to 100 μm, or 40 to 80 μm.

[0039] In one embodiment of the present invention, a method of preparing lignin is preferably a method of purchasing a commercially available product, such as Sunex and Vanillex (both manufactured by Nippon Paper Industries Co., Ltd.).

[0040] (Bentonite) According to one embodiment of the present invention, the treatment agent contains bentonite. Bentonite contains a large amount of layered aluminum phyllosilicate and has properties such as high viscosity, adhesion, water absorption, and adsorption. Bentonite adsorbs cations such as ammonia, and suppresses and adsorbs the generation of ammonia and other odorous substances. Furthermore, by combining lignin with bentonite, the cation adsorption effect of bentonite and the complex, yet unexplained, three-dimensional network structure of lignin work together to further suppress the generation of ammonia and other odorous substances, adsorb, and decompose them.

[0041] According to one embodiment of the present invention, the bentonite content (mass%) in the treatment agent is 0.01% by mass or more, 0.05% by mass or more, 0.1% by mass or more, 0.5% by mass or more, 0.8% by mass or more, 1% by mass or more, 1.2% by mass or more, 1.5% by mass or more, or 1.8% by mass or more. According to one embodiment of the present invention, the bentonite content (mass%) in the treatment agent is 30% by mass or less, 25% by mass or less, 20% by mass or less, 15% by mass or less, 10% by mass or less, 8% by mass or less, 6% by mass or less, 4% by mass or less, 3.5% by mass or less, 3.3% by mass or less, 3.1% by mass or less, 2.8% by mass or less, 2.6% by mass or less, or 2.4% by mass or less.

[0042] According to one embodiment of the present invention, the content (mass%) of bentonite in the treatment agent is 0.01 to 30% by mass, 0.05 to 25% by mass, 0.1 to 20% by mass, 1 to 15% by mass, 1.5 to 10% by mass, 1.5 to 8% by mass, 1.5 to 6% by mass, 1.5 to 4% by mass, or 1.5 to 3.5% by mass. According to one embodiment of the present invention, the content (mass%) of bentonite in the treatment agent is 1 to 3.5% by mass.

[0043] According to one embodiment of the present invention, the bentonite has an average particle size of 0.05 to 300 μm, 0.5 to 200 μm, 10 to 150 μm, 50 to 148 μm, or 80 to 145 μm. According to one embodiment of the present invention, the bentonite has a volume-average particle size (D50) of 0.05 to 300 μm, 0.5 to 200 μm, 10 to 150 μm, 50 to 148 μm, or 80 to 145 μm. According to one embodiment of the present invention, the bentonite has a mode diameter of 0.05 to 300 μm, 0.5 to 200 μm, 10 to 150 μm, 50 to 148 μm, or 80 to 145 μm.

[0044] In one embodiment of the present invention, a method of preparing bentonite is preferably a method of purchasing a commercially available product, such as Kunipia-F, Kunimine F, Moistnite S, and Moistnite U (all manufactured by Kunimine Industries), or 250SA-B (all manufactured by Hoyo Bentonite Mining Co., Ltd.).

[0045] (Zeolite) According to one embodiment of the present invention, the treatment agent contains zeolite. "Zeolite" is a general term for minerals called zeolites, and approximately 40 types of natural zeolites have been discovered. By including zeolite, the pores of the zeolite can capture and suppress malodors. The zeolite may be natural or artificial, but from the standpoint of availability, artificial zeolites are preferred. Furthermore, the zeolite of the present invention is preferably a zeolite called mordenite, which has tunnel-shaped, extremely tiny cavities of approximately 5.5 to 8 Å, slightly larger than water or nitrogen molecules. When purchasing commercially available zeolites, Zeolite 2460, Zeolite 60, Zeolite CP, and Zeofil (registered trademark) series manufactured by Shin Tohoku Chemical Industry Co., Ltd. are preferred. The average particle size of the zeolite is not particularly limited, but is preferably approximately 5 μm to 1.5 mm, approximately 8 μm to 1.2 mm, or approximately 10 to 100 μm. Zeolites include SiO 2 (silicon oxide), Al 2 O 3 (aluminum oxide), CaO (calcium oxide), Na 2 O (sodium oxide), K 2O (potassium oxide), Fe 2 O 3 (iron oxide), MgO (magnesium oxide), adhering water (H 2 O), bound water (H 2 O), and others are contained in amounts of about 70.5 mass%, 11.3 mass%, 2.6 mass%, 1.6 mass%, 1.3 mass%, 0.7 mass%, 0.1 mass%, 8.0 mass%, and 3.9 mass%, respectively, but of course, the composition is not limited to these, and it is also possible to use a composition prepared so that each component accounts for about 0.1 to 20% and the total amount is 100%. 2 O 6 Zeolites such as] may also be used.

[0046] According to one embodiment of the present invention, the zeolite content (mass%) in the treating agent is 0.01% by mass or more, 0.05% by mass or more, 0.1% by mass or more, 0.5% by mass or more, 1% by mass or more, 1.5% by mass or more, 2% by mass or more, 3% by mass or more, 3.5% by mass or more, 4% by mass or more, 4.5% by mass or more, 5% by mass or more, 5.5% by mass or more, 6% by mass or more, 6.5% by mass or more, 7% by mass or more, 7.5% by mass or more, or 8% by mass or more. According to one embodiment of the present invention, the zeolite content (mass%) in the treating agent is 40% by mass or less, 30% by mass or less, 25% by mass or less, 20% by mass or less, 15% by mass or less, 13% by mass or less, 12% by mass or less, 10% by mass or less, 9% by mass or less, or 8.5% by mass or less.

[0047] According to one embodiment of the present invention, the content (mass%) of zeolite in the treating agent is 0.01 to 40 mass%, 0.05 to 30 mass%, 0.1 to 20 mass%, 0.5 to 15 mass%, 1 to 13 mass%, 1.5 to 12 mass%, 2 to 9 mass%, 3 to 9 mass%, or 3.5 to 8.5 mass%. According to one embodiment of the present invention, the content (mass%) of zeolite in the treating agent is 1 to 20 mass%.

[0048] (Humic Acid) According to one embodiment of the present invention, the treatment agent includes humic acid. Humic acid is an end product formed through microbial decomposition of plants and the like, and may be an organic fraction that cannot be classified as sugar, carbohydrate, protein, lipid, etc. Humic acid has a strong chelating ability with metal ions, has many functional groups, and can produce sugars and amino acids upon hydrolysis.

[0049] According to one embodiment of the present invention, the average particle size of the humic acid-containing material is about 100 nm to 3 mm, about 0.01 to 1 mm, about 100 to 900 μm, about 200 to 800 μm, or about 400 to 600 μm. According to one embodiment of the present invention, the humic acid-containing material has an average particle size of 1 to 15 mass%, 5 to 14 mass%, or 7 to 12 mass% that passes through a 42 mm mesh sieve and on a 0.6 mm mesh sieve, 15 to 45 mass%, 30 to 43 mass%, or 40 to 42 mass% that passes through a 0.6 mm mesh sieve, and 20 to 60 mass%, 35 to 55 mass%, or 46 to 52 mass% that passes through a 0.03 mm mesh sieve.

[0050] In one embodiment of the present invention, the method for preparing the material containing humic acid is preferably a commercially available method.

[0051] According to one embodiment of the present invention, the content (mass %) of the material containing humic acid in the treatment agent is 0.01% by mass or more, 0.05% by mass or more, 0.1% by mass or more, 0.5% by mass or more, 1% by mass or more, 1.5% by mass or more, 3% by mass or more, 4% by mass or more, 5% by mass or more, 6% by mass or more, 6.5% by mass or more, 7% by mass or more, 7.5% by mass or more, 8% by mass or more, 8.5% by mass or more, or 9% by mass or more. According to one embodiment of the present invention, the content (mass %) of the material containing humic acid in the treatment agent is 30% by mass or less, 25% by mass or less, 20% by mass or less, 15% by mass or less, 13% by mass or less, 12% by mass or less, 10% by mass or less, 8% by mass or less, or 7% by mass or less.

[0052] According to one embodiment of the present invention, the content (mass %) of the material containing humic acid in the treatment agent is 0.01 to 30 mass %, 0.05 to 25 mass %, 0.1 to 20 mass %, 3 to 15 mass %, 4 to 13 mass %, or 5 to 12 mass %. According to one embodiment of the present invention, the content (mass %) of the material containing humic acid in the treatment agent is 1 to 20 mass %.

[0053] According to one embodiment of the present invention, the treatment agent contains lignin, bentonite, and humic acid. Such a combination can more efficiently suppress malodors such as ammonia from the object to be treated.

[0054] (Disodium hydrogen phosphate) According to one embodiment of the present invention, the treatment agent contains disodium hydrogen phosphate. According to one embodiment of the present invention, the average particle size of disodium hydrogen phosphate is about 100 nm to 3 mm, about 0.01 to 1 mm, about 100 to 900 μm, about 200 to 800 μm, or about 400 to 600 μm, but is not limited to these and may deviate from these ranges, and commercially available products of any size can be used as appropriate.

[0055] According to one embodiment of the present invention, the content (mass%) of disodium hydrogen phosphate in the treatment agent is 0.01% by mass or more, 0.05% by mass or more, 0.1% by mass or more, 0.5% by mass or more, 1% by mass or more, 1.5% by mass or more, 3% by mass or more, 4% by mass or more, or 5% by mass or more. According to one embodiment of the present invention, the content (mass%) of disodium hydrogen phosphate in the treatment agent is 30% by mass or less, 25% by mass or less, 20% by mass or less, 15% by mass or less, 13% by mass or less, 12% by mass or less, 10% by mass or less, 8% by mass or less, or 7% by mass or less.

[0056] According to one embodiment of the present invention, the content (mass %) of disodium hydrogen phosphate in the treatment agent is 0.01 to 30 mass %, 0.05 to 25 mass %, 0.1 to 20 mass %, 3 to 15 mass %, 4 to 13 mass %, or 5 to 12 mass %. According to one embodiment of the present invention, the content (mass %) of disodium hydrogen phosphate in the treatment agent is 1 to 10 mass %.

[0057] (Sodium dihydrogen phosphate) According to one embodiment of the present invention, the concentration of sodium dihydrogen phosphate is less than 1% by mass. According to one embodiment of the present invention, the treatment agent is substantially free of sodium dihydrogen phosphate.

[0058] (Baking soda) According to one embodiment of the present invention, the treatment agent contains baking soda (sodium bicarbonate). Baking soda has the composition formula NaHCO 3 Baking soda is a sodium bicarbonate represented by the formula: Baking soda is safe for the human body, as it is sometimes used as a food additive. Therefore, baking soda is preferred because it is less likely to cause chemical burns. Baking soda can be prepared by purchasing a commercially available product, and preferred examples include industrial-grade baking soda manufactured by Tosoh Corporation, QINDAO HAI WAN GROUP IMP. & EXP. CO., and Zichuan Antou Alum Factory Co., Ltd. According to one embodiment of the present invention, the average particle size of baking soda is not particularly limited, but is preferably 30 to 150 μm, and more preferably 80 to 100 μm.

[0059] According to one embodiment of the present invention, the content (mass%) of sodium bicarbonate in the treatment agent is 0.01% by mass or more, 0.05% by mass or more, 0.1% by mass or more, 0.5% by mass or more, 1% by mass or more, 1.5% by mass or more, 2% by mass or more, 3% by mass or more, 3.5% by mass or more, 4% by mass or more, or 4.5% by mass or more. According to one embodiment of the present invention, the content (mass%) of sodium bicarbonate in the treatment agent is 40% by mass or less, 38% by mass or less, 35% by mass or less, 33% by mass or less, 30% by mass or less, 29% by mass or less, 28% by mass or less, 25% by mass or less, 20% by mass or less, 18% by mass or less, 15% by mass or less, 13% by mass or less, 12% by mass or less, 11% by mass or less, or 10% by mass or less.

[0060] According to one embodiment of the present invention, the content (mass%) of baking soda in the treatment agent is 0.01 to 40 mass%, 0.05 to 38 mass%, 0.1 to 35 mass%, 0.5 to 30 mass%, 1 to 28 mass%, 1.5 to 25 mass%, 2 to 20 mass%, 3 to 18 mass%, 3.5 to 15 mass%, 4 to 12 mass%, or 4.5 to 10 mass%. According to one embodiment of the present invention, the content (mass%) of baking soda in the treatment agent is 1 to 20 mass%.

[0061] Limonite According to one embodiment of the present invention, the treatment agent includes limonite.

[0062] The chemical composition of limonite is FeO(OH)nH 2 O, but hematite (Fe 2 O 3 It may contain impurities such as manganese (II) oxide, clay minerals, etc. The inclusion of limonite allows for the decomposition and adsorption of sulfur-based compounds such as mercaptan, methyl mercaptan, and hydrogen sulfide, which are odor-causing components in feces, as well as fatty acid compounds.

[0063] According to one embodiment of the present invention, the limonite content (mass%) in the treatment agent is 0.01% by mass or more, 0.05% by mass or more, 0.1% by mass or more, 0.5% by mass or more, 1% by mass or more, 1.5% by mass or more, 2% by mass or more, 3% by mass or more, 3.5% by mass or more, 4% by mass or more, or 4.5% by mass or more. According to one embodiment of the present invention, the limonite content (mass%) in the treatment agent is 40% by mass or less, 38% by mass or less, 35% by mass or less, 30% by mass or less, 28% by mass or less, 25% by mass or less, 20% by mass or less, 18% by mass or less, 15% by mass or less, 13% by mass or less, 12% by mass or less, 10% by mass or less, 5% by mass or less, 2% by mass or less, or less than 1% by mass.

[0064] According to one embodiment of the present invention, the content (mass%) of limonite in the treatment agent is 0.01 to 40 mass%, 0.05 to 38 mass%, 0.1 to 35 mass%, 0.5 to 30 mass%, 1 to 28 mass%, 1.5 to 25 mass%, 2 to 20 mass%, 3 to 18 mass%, 3.5 to 15 mass%, 4 to 12 mass%, or 4.5 to 10 mass%. According to one embodiment of the present invention, the concentration of limonite in the treatment agent is less than 1 mass%. According to one embodiment of the present invention, the treatment agent is substantially free of limonite.

[0065] According to one embodiment of the present invention, the volume average particle size (D50) of limonite measured by particle size distribution is preferably 0.1 to 200 μm, more preferably 1 to 150 μm, even more preferably 5 to 100 μm, and even more preferably 10 to 50 μm. By being in such a range, the desired effects of the present invention can be efficiently achieved.

[0066] Limonite can be freely selected from commercially available products, such as LMB50 and LMB300 (both manufactured by Nippon Limonite Co., Ltd.).

[0067] According to one embodiment of the present invention, the treatment agent is in an air-dried state (a state in which the treatment agent placed in the atmosphere loses moisture through natural drying and maintains equilibrium with the humidity of the atmosphere).

[0068] <Lump-shaped Processing Agent> According to one embodiment of the present invention, the processing agent may be granulated using a binder such as water, PVA, cellulose, water-soluble cellulose, or sodium alginate. That is, according to one embodiment of the present invention, the processing agent is a lump-shaped processing agent. Furthermore, the processing agent according to one embodiment of the present invention may be in the form of a granular processing agent or a lump-shaped processing agent using the technology of JP 2013-6137 A or JP 2011 / 162244 A. According to one embodiment of the present invention, the processing agent contains a lubricant. The lubricant is used when preparing the lump-shaped processing agent, particularly to facilitate smooth feeding into the die of the tablet press. Therefore, the type of lubricant may be appropriately selected from conventionally known types or may be used in combination. For example, ester-based, silicon-based, stearic acid ester, calcium stearate, potassium stearate, calcium, zinc, etc. may be used. The content of the lubricant is approximately 0.3 to 5 mass%, approximately 0.8 to 4.5 mass%, or approximately 0.8 to 3 mass% relative to the total amount of the processing agent.

[0069] According to one embodiment of the present invention, the average diameter of the treatment agent is 0.01 to 100 mm, 0.1 to 50 mm, 1 to 30 mm, 3 to 20 mm, or 5 to 20 mm. In this specification, unless otherwise specified, "average diameter" refers to an average value obtained by arbitrarily selecting a statistically reliable number of particles (or 10, 100, 200, 300, or 1000 particles), measuring the longest particle diameter for each particle with a vernier caliper, and taking the arithmetic mean of the measured diameters.

[0070] According to one embodiment of the present invention, the treatment agent is prepared using a benchtop manual tablet press. To prepare a bulk treatment agent using a benchtop manual tablet press (with one punch and one die), first, the components to be solidified are manually spooned into the punch. Then, the lever is manually (hydraulically) lowered to apply pressure, solidifying the components and preparing the bulk treatment agent. For example, when using a small-diameter punch (7 mm diameter: upper and lower circular type), the smaller the diameter, the higher the pressure applied per area, so even materials that are difficult to solidify tend to solidify. On the other hand, when using a large-diameter punch (15 mm diameter: upper and lower flat type), the larger the diameter, the lower the pressure applied per area, which is disadvantageous for materials that are difficult to solidify. However, the larger diameter facilitates feeding the material into the punch, improving productivity.

[0071] According to one embodiment of the present invention, the treatment agent is prepared using a continuous tablet press. The continuous tablet press may or may not be a direct compression type, but it is preferable to employ a direct compression type, which improves productivity by eliminating the need for pretreatment. It is also preferable to add a lubricant to facilitate the feeding of fine powder. On the other hand, when pretreatment is performed, for example, a lubricant may be added to granulate the fine powder by rolling under high pressure using a roller compactor, and then mixing the granulated powder with a binder (binding agent), followed by tableting. Considering mass production, it is preferable to use a tablet press (such as model AP18-SS) manufactured by Hata Iron Works Co., Ltd. In this case, the diameter of the punch and die is approximately 13 mm, and the number of punches is approximately 18. Using such a tablet press is preferable because it allows production by simply preparing and mixing the raw materials to the desired ratio, placing the mixed raw materials in the hopper of the tablet press, and rotating the tablet press to tablet.

[0072] According to one embodiment of the present invention, the treatment agent is prepared using a continuous rotary tablet press. As described above, there are no particular limitations on the method for preparing the treatment agent (lump treatment agent). The treatment agent may be prepared by mixing the components constituting the treatment agent in any order, or by mixing the desired components, including a binder, while tableting using a tablet press.

[0073] (Binder) According to one embodiment of the present invention, the binder is preferably a cellulose-based binder, which has the effect of binding together some or all of the components contained in the treatment agent.

[0074] According to one embodiment of the present invention, the binder may be prepared by purchasing a commercially available product, such as PH-102, TG-101, ST-02, or TG-101 manufactured by Asahi Kasei Chemicals Corporation, PVPK-15, PVPK-30, or PVPK-90 (polyvinylpyrrolidone) manufactured by Higuchi Shokai Co., Ltd., KC series (KC Flock W-50S, W-50, W-100 / 100G, W-200 / 200G, W-250, W-300G, or W-400G) manufactured by Nippon Paper Chemicals Co., Ltd., or Cerrossa series (Cerrossa K2) manufactured by Asahi Kasei Chemicals Corporation.

[0075] The main function of the binder is to contribute to solidification. Therefore, the smaller the amount, the better. According to one embodiment of the present invention, the binder content (mass %) in the treatment agent is 5 mass % or more, 10 mass % or more, 15 mass % or more, 20 mass % or more, or 25 mass % or more. According to one embodiment of the present invention, the binder content (mass %) in the treatment agent is 60 mass % or less, 55 mass % or less, 50 mass % or less, or 45 mass % or less. According to one embodiment of the present invention, the binder content (mass %) in the treatment agent is 10 to 50 mass %.

[0076] According to one embodiment of the present invention, the treatment agent is not in a lump form. According to one embodiment of the present invention, the treatment agent may be in the form of a mixture obtained by simply mixing the components constituting the treatment agent without applying pressure or the like. According to one embodiment of the present invention, the treatment agent is substantially free of a binder that functions to bind some or all of the components constituting the treatment agent. In this specification, the expression "substantially free of" means not only the concept of not containing the component at all, but also the concept of containing 0.005 mass% or less of the component in the treatment agent.

[0077] According to one embodiment of the present invention, the lump treatment agent is in an air-dried state (a state in which the treatment agent placed in the air loses moisture through natural drying and maintains equilibrium with the humidity of the air).

[0078] <Treatment with a Treating Agent> There are no particular limitations on the specific treatment method, but according to one embodiment of the present invention, a method of bringing the waste liquid into contact with a treating agent is preferred. According to one embodiment of the present invention, a method of adding a treating agent to the waste liquid is exemplified. According to one embodiment of the present invention, a method of adding the waste liquid to the treating agent is exemplified. According to one embodiment of the present invention, a treating agent is placed in advance in a bottle that collects waste liquid discharged from a person during a surgical procedure (e.g., endoscopic treatment). Waste liquid discharged by suction or the like is introduced into a bottle in which the treating agent of the present invention has been placed in advance, and the waste liquid is treated.

[0079] For example, during endoscopic examinations, waste fluids (such as feces, blood, and bodily fluids) are discharged from the digestive tract (stomach, rectum, large intestine, small intestine, etc.) after the examination, and this waste fluid is subjected to waste disposal. In hospitals, waste fluids such as urine from hospitalized patients are also subjected to waste disposal. These waste fluids may contain spore-forming bacteria, such as those of the Bacillus and Clostridium genera. Spore-forming bacteria are representative of bacteria that cause opportunistic infections. Spore-forming bacteria are heat-resistant bacteria that can withstand temperatures above 100°C, and they form spores within their cells when nutrients are lacking or the environment deteriorates. These spores are resistant not only to heat but also to desiccation and disinfectants, allowing them to survive in harsh environments until they find an environment suitable for growth. When the growth environment, including moisture, temperature, and nutrients, is suitable, they germinate, become vegetative cells, and multiply. Therefore, spore-forming bacteria require special attention in hospital infection control. The treatment agent of the present invention can suppress or inhibit the germination or proliferation of spore-forming bacteria by contacting such wastewater. Therefore, it is particularly useful in hospitals that require the treatment of large amounts of patient wastewater. The reason why the treatment agent of the present invention exhibits an inhibitory effect on the germination or proliferation of spore-forming bacteria is unclear, but is speculated as follows. The present invention is not limited by this speculation. The treatment agent of the present invention contains slaked lime and pepper. The presence of slaked lime renders the wastewater alkaline. Therefore, the spore coats (outer and inner layers) of spore-forming bacteria placed in an alkaline atmosphere soften, facilitating the penetration of substances from the outside world. This allows the pepper and zinc oxide (if further included) in the treatment agent to directly act on the core, effectively suppressing or inhibiting spore germination and bacterial proliferation (growth).

[0080] That is, the treating agent according to the present invention is used to suppress or inhibit the spore germination or proliferation of spore-forming bacteria. The present invention also provides a method for suppressing or inhibiting the spore germination or proliferation of spore-forming bacteria, which comprises contacting a waste liquid with the treating agent according to the present invention. Examples of spore-forming bacteria include known spore-forming bacteria of the genera Amphibacillus, Bacillus, Clostridium, and Sporosarcina. Among these, the treating agent according to the present invention exhibits excellent suppression or inhibition of spore germination or proliferation against bacteria of the genus Clostridium, particularly Clostridioides difficile.

[0081] According to one embodiment of the present invention, the amount of treatment agent relative to the object to be treated (e.g., wastewater discharged during endoscopic examination: approximately 1000 mL to approximately 4000 mL) can be adjusted as needed, but as a guideline, it is 1 to 1000 g, 2 to 900 g, 3 to 800 g, 5 to 750 g, 10 to 700 g, 20 to 650 g, or 30 to 600 g. According to one embodiment of the present invention, after contacting the object to be treated with the treatment agent (and then mixing as necessary), the treatment agent may be allowed to stand for, for example, 5 minutes to 30 days, 120 minutes to 20 days, 300 minutes to 10 days, 200 minutes to 5 days, 400 minutes to 3 days, or 500 minutes to 2 days. The treatment agent of the present invention also has the effect of suppressing malodor from the object to be treated for a long period of time.

[0082] In this embodiment, the treatment agent may further contain other components. Here, the other components include an antibacterial agent. When the treatment agent further contains an antibacterial agent, the antibacterial agent is not particularly limited, and examples thereof include inorganic antibacterial agents such as silver and copper, natural antibacterial agents such as chitin, chitosan, allyl isothiocyanate, hinokitiol, and limonene, and penicillin and macrolide antibacterial agents. When the treatment agent further contains an antibacterial agent, the amount of the antibacterial agent is not particularly limited and can be appropriately selected depending on the desired effect of suppressing or inhibiting spore germination or proliferation.

[0083] Preparation of artificial waste liquid (control (i)) 4 g of soy protein hydrolysate (hypopolypeptone), 0.8 g of garlic paste, and 0.2 g of urea were dissolved in 1 L of pure water. 1.0 g of black soil was added to 25 mL of this solution to prepare control (i).

[0084] <Preparation of Controls (ii) and (iii)> Control (ii) was prepared by adding one tablet (0.72 g) of Control Treatment Agent 1 to Control (i), and control (iii) was prepared by adding 0.72 g of Control Treatment Agent 2 to Control (i).

[0085] (Preparation of Control Treatment Agent 1) Control treatment agent 1 (average diameter: 15 mm, average thickness: 5 mm) was prepared by placing the following components in the mortar of a tabletop tablet press (manufactured by Kikusui Seisakusho Co., Ltd.) and compressing under a pressure of 40 kN to obtain 70 tablets. The punch used was a top-bottom flat type with a diameter of 15 mm.

[0086]

[0087] (Preparation of Control Treatment Agent 2) The components constituting the treatment agent were mixed so as to have the composition shown in the table below, to prepare 100 g of the treatment agent.

[0088]

[0089] <Addition of Various Drugs> Various drugs shown in the table below were further added to the control (ii) and control (iii) in the amounts and concentrations shown in the table below.

[0090]

[0091] First, Table 5 shows the odor intensity measurements for the control (ii)-based experiment.

[0092] The odor intensity was determined by scoring based on the following criteria by multiple people (3 people) who passed the odor panel selection test, and the arithmetic mean of the scores was used to determine the odor intensity.

[0093]

[0094]

[0095]

[0096] Looking at the changes in odor intensity in Table 5, control (i) maintained an odor intensity of around 3.5 from day 1 to day 11. Control (ii) showed a significant effect with an odor intensity of 2 on day 1, but the intensity gradually increased, reaching the same level as control (i) on day 5 and the highest of all the systems on day 8.

[0097] In the control (ii) system with various chemicals added, CaO and iron oxide, which were added to improve the reducing atmosphere that is prone to the production of malodorous substances, were less effective, being either worse or equal to control (ii). The activated carbon system, which maintained odor intensity approximately 0.5 lower than control (ii) until the eighth day, appeared to have some effect, but on the eighth day, mold began to grow and an unpleasant odor was emitted. Therefore, testing of the activated carbon system was discontinued. In other cases, the odor quality changed due to the chemical itself or mold growth, resulting in increased discomfort. Systems with copper salts, silver salts, alum, chlorine agents, or disinfectants added for sterilization purposes all suppressed fecal and putrid odors more than control (ii), but the strong odor of the chemicals, such as chlorine agents, increased the odor intensity in some cases, and the results were not satisfactory.

[0098] Regarding the quality of the smell, the smell of feces and the smell of a pit toilet began to be detected from around the fourth day in the control (i), and although the odor intensity in the control (ii) was lower, the smell of a pit toilet began to be detected from the same period.

[0099] The systems containing CaO or silver salts showed no significant difference from the control (ii) in terms of odor quality, while the systems containing iron oxide or alum suppressed the toilet odor for a few days but then emitted a similar odor. The systems containing activated carbon or copper salts suppressed the toilet odor slightly, but were not considered very effective because they emitted a different odor or caused mold to grow. The systems containing dichloroisocyanuric acid did not produce much of the toilet odor, but had relatively strong chlorine and burnt odors.

[0100] On the other hand, regarding the state during use, in the control (ii), water began to come out to the top on the fourth day, and by the sixth day it had separated into three layers, with water visible in the middle layer. In contrast, in the CaO-added system, it had separated into three layers on the fourth day, and the water content was also high. This is thought to be due to calcium being coordinated to the high molecular weight water-absorbent resin (water-absorbent polymer), resulting in a decrease in the amount of water absorption. A similar phenomenon was also observed in the system to which copper salt was added. In the other systems, no significant difference was observed in the water retention portion compared to the control.

[0101] Next, the odor intensity measurement results for Control Treatment 2 are shown in Table 7.

[0102]

[0103]

[0104]

[0105] Control treatment agent 2 (control (iii)) suppressed odors second only to activated carbon on the first day alone, but the odor intensity increased significantly on days 4 and 5. Perhaps because the odor was strong, it decreased slightly from day 8 onwards, but it was thought that control treatment agent 2 (control (iii)) had little effect in suppressing the generation of malodor over the long term.

[0106] In the control (iii) systems where various chemicals were added, the odor intensity was generally low, except for the systems where CaO or zeolite was added. Among these, the systems where silver salts were added, activated carbon was added, or cationic surfactants (disinfectant-added systems) showed relatively good results.

[0107] However, in terms of the quality of the smell, in the control (iii) a strong feces smell, a pit toilet smell, and irritation were felt on the fourth day, while in the systems to which zeolite, CaO, iron oxide, activated carbon, copper salt, silver salt, or alum had been added, the pit toilet smell was felt from the same period, although the strength varied.

[0108] In the system where dichloroisocyanuric acid was added, a chemical odor was felt continuously at a constant intensity, while in the system where benzalkonium chloride was added, a garlic odor persisted for a long time, and the decomposition of organic matter was inhibited, and the generation of fecal odor was also suppressed, but by the 11th day, a toilet-related odor was emitted.

[0109] Regarding the state at the time of use, the system to which CaO was added hardly retained water and was in a watery state. The other systems were not significantly different from the control (iii).

[0110] In the above tests, the water absorption effect was weakened in the system to which CaO was added, and there was no effect on odor, so further investigation was terminated. The system to which iron oxide was added also had a slight effect, so further investigation was terminated. The effect of copper salt was equivalent to that of silver, but it inhibited the water-absorbent resin, so further investigation was terminated.

[0111] The above was the first test, followed by a second test in which silver salt, alum, dichloroisocyanuric acid, or benzalkonium chloride were added to the system, and the effects were confirmed by varying the concentration. Additionally, CMC (sodium carboxymethylcellulose) glue, which is predicted to increase viscosity and inhibit mass transfer, sodium chloride, which is predicted to increase salt concentration and reduce microbial activity, soluble oxidizing iron salts, benzethonium chloride, a cationic surfactant similar to benzalkonium chloride, and sodium percarbonate, which generates hydrogen peroxide in water, were tested individually as control (ii) agents (single systems). Furthermore, the effects of combinations of benzalkonium chloride and activated carbon, sodium chloride and activated carbon, sodium percarbonate and activated carbon, sodium percarbonate and benzalkonium chloride, and sodium percarbonate and silver salt were also confirmed when added to control (ii) (combined systems).

[0112] The conditions for these second odor inhibition tests are shown in the table below.

[0113]

[0114] The comfort level was determined by scoring the odors according to the following criteria by three people who passed the odor panel selection test, and the arithmetic mean of the scores was used to determine the comfort level.

[0115]

[0116]

[0117]

[0118] In the control (ii), the smell of the septic toilet was strong from the third to the seventh day, and after that, the smell of rotting vegetables and the like was detected, possibly because some of the toilet-related odorous components had evaporated during that time.

[0119] In the systems containing silver salt, alum, sodium chloride, or iron chloride, the odor of a septic tank began to be detected on about the third day, and the test was stopped on the seventh to eleventh day due to the appearance of mold and a change in odor.

[0120] In the system containing CMC glue, although there was an odor reminiscent of plastic or rubber, the smell of a pit toilet was not noticeable until about the eighth day, but after that the smell of a pit toilet and putrefaction became stronger.

[0121] In the systems containing benzalkonium chloride or benzethonium chloride, a chemical odor was always noticeable, but the septic tank odor was relatively suppressed, with the benzethonium chloride system being more effective. In the system containing sodium percarbonate, a distinctive, unpleasant chemical odor was noticeable, but the septic tank odor itself was relatively suppressed for up to about two weeks.

[0122]

[0123] In the systems where the compounds were added in combination, mold often grew during the test, and no particular effect of combining compounds was found in this system.

[0124] Odor intensity is an index of the strength of an odor, and there are cases where a strong odor is not perceived as unpleasant, and cases where a weak odor is perceived as unpleasant. Therefore, further investigation focused on the pleasantness or unpleasantness of odors.

[0125] In addition to the control (ii), various natural chemicals were added, including tea (100% green tea leaves), perilla, chili pepper, black pepper, Houttuynia cordata, powdered mustard, and powdered wasabi, and the pleasantness or unpleasantness of the odor was evaluated in the same manner as above. The amount of each of these added to the control (ii) was 0.1 g.

[0126]

[0127] As a result, the system containing pepper had the best pleasantness rating, with almost no unpleasantness felt for about 10 days. Looking at the odor quality (quality of smell), the system containing pepper, which did not have a high unpleasantness rating, was perceived as mainly a peppery smell. The composition of the system containing pepper is summarized below.

[0128]

[0129] In the above table, if the binder (KC200 (KC Flock)) is removed and the content ratio of each component is converted, the results are as follows:

[0130]

[0131] Next, further investigation was carried out to determine whether there was a system better than pepper. Specifically, since control (ii) contains slaked lime (an alkaline component), it was investigated whether adding more alkali would suppress putrefaction and thereby suppress the malodor, and whether potassium iodide could react with organic matter to exert a bactericidal effect as an iodine agent and suppress the malodor. Specifically, in addition to control (ii), various chemicals were added, including sodium sesquicarbonate, baking soda, and potassium iodide, and the pleasantness and unpleasantness of the odor were evaluated in the same manner as above. The amount of chemical added to control (ii) was 0.1 g in all cases.

[0132]

[0133] As shown in Table 15, the pleasantness / unpleasantness scores of these were equal to or lower than that of the control (ii), and no effect was observed. There was also no significant difference in odor quality.

[0134] Next, an experiment was conducted in which a thickening agent with a thickening effect was added, aiming to reduce the amount of volatile malodor by reducing the mobility of malodorous components in the liquid due to increased viscosity. Specifically, in addition to the control (ii), various agents containing hi-metolose, PVA, and starch were prepared, and the pleasantness and unpleasantness of the odor were evaluated in the same manner as above. The amounts of agents added to the control (ii) were 0.1 g for hi-metolose and starch, and 0.1 ml for PVA.

[0135]

[0136] So, I didn't get the results I expected.

[0137] Next, experiments were conducted with various surfactants, aiming to evaluate the odor-suppressing effect of methods such as surfactants for reducing viable bacterial counts. Specifically, in contrast to the control (ii), various chemicals were added, including 0.1 g of Triton X100 (Kishida Chemical), a representative nonionic surfactant; 0.1 g of soap (commonly available commercially available fatty acid ester soap shaved into powder); and two cationic surfactant samples (cation G50: benzalkonium chloride solution, Osmolin DA-50: didecyldimethylammonium adipate). The two cationic surfactant samples were used at the following concentrations. Note that since various surfactants were added to 25 mL of artificial waste liquid, the actual addition amounts can be calculated from the above concentrations.

[0138]

[0139] When the test results were examined in terms of comfort level, the system containing 300 mg / L of Triton X and DA-50 showed slightly better results than the control (ii). When compared with the systems containing G-50 or DA-50 at 100 mg / L, the system containing DA-50 was slightly better. It should be noted that benzalkonium chloride solution is known to be used as a disinfectant for hands and for disinfecting contaminated environments.

[0140] Taking all of the above results together, we have concluded that pepper has the greatest effect in reducing bad odors.

[0141] Therefore, each component of the following composition, including pepper, was placed in the mortar of a tabletop tablet press (manufactured by Kikusui Seisakusho Co., Ltd.) and tableted under a pressure of 40 kN to obtain 50 g (70 tablets) of block-shaped treatment agents KS-22-α1, KS-22-α2, and KS-22-α3. Also, 50 g (70 tablets) of tab22, which does not contain pepper, were obtained (average diameter: 15 mm, average thickness: 5 mm). The punch used was a top-bottom flat type with a diameter of 15 mm.

[0142]

[0143] In addition, if the binder (KC200 (KC Flock)) is excluded from Table 18 above and the content ratio of each component is converted, the results are as follows.

[0144]

[0145]

[0146] In addition, if the binder (KC200 (KC Flock)) is excluded from Table 20 above and the content ratio of each component is converted, the results are as follows.

[0147]

[0148]

[0149] In addition, in Table 22 above, if the binder (KC200 (KC Flock)) is removed and the content ratio of each component is converted, the results are as follows.

[0150]

[0151]

[0152] To the control (i), one tablet (0.72 g) of each of the above bulk treatment agents was added.

[0153] As in the previous experiments, the pleasantness and unpleasantness of these samples were measured by several people (3 people) who had passed the odor panel selection test.

[0154]

[0155] <Preparation of simulated feces> Next, for the simulated feces to be used in the test, fatty acids, indole, and skatole were added in amounts sufficient to contribute to the odor to a certain extent to stone powder clay, which has a texture and specific gravity similar to that of feces, and mixed together. The prepared concentrations are shown in the table below.

[0156]

[0157] In the test, 65 g of simulated feces was placed in a plastic bag, and a specified amount (50 g) of each of Control Treatment 1, KS-22-α1, and KS-22-α1 powder type + silver salt (silver nitrate added at 0.5% by mass relative to the total mass of KS-22α1 powder type (uncompressed)) was added, followed by the addition of 200 mL of pure water and immediate placement in a 17 L container. In this manner, the control (no treatment added), Control Treatment 1, KS-22-α1, and KS-22-α1 powder type + silver salt were evaluated.

[0158] <Test Results> The measurement results for the concentrations of n-butyric acid, n-valeric acid, isovaleric acid, indole, and skatole, as well as the inhibition rates relative to the odorant control, are shown in the table below.

[0159] (n-Butyric Acid) For n-butyric acid, the volatile concentration of the control (200 mL of purified water added to simulated feces) was 0.34 ppm at 4 hours and remained around 0.7 ppm from the third day onwards. In contrast, Control Treatment 1 showed 0.15 ppm at 4 hours, 0.07 ppm at the third day, and approximately 0.04 ppm from one week onwards. For the KS-22-α1 and KS-22-α1 powder type + silver salt systems, the volatile concentration was 0.03 ppm or less at 4 hours and generally 0.01 ppm or less from the first day onwards, which were low levels. In terms of inhibition rate, the KS-22-α1 powder type + silver salt system showed 98% or more from the first day onwards.

[0160] The control treatment 1 system generally had an inhibition rate of over 90% from the first day onwards, but the KS-22-α1 system showed an inhibition rate that was about 10% higher. While this may seem like only about 10%, it actually means that the odor was reduced to 1 / 10 or 1 / 50 of the control odor, and considering that human response to odors is exponential and the odor intensity and concentration guidelines of the Offensive Odor Prevention Act, it is believed that an improvement was achieved in the sensory evaluation (odor intensity) of n-butyric acid, lowering it by about one level.

[0161] (n-Valeric Acid) For n-valeric acid, the control showed 0.4 ppm at 4 hours and around 1.3 ppm from day 1 onwards. In contrast, Control Treatment 1 showed low levels of 0.08 ppm at 4 hours and 0.03 ppm or less from day 1 onwards. KS-22-α1 and KS-22-α1 powder type + silver salt showed even better performance than Control Treatment 1, with levels of roughly 0.01 ppm or less from day 4 onwards. Looking at the inhibition rate relative to the control, Control Treatment 1 showed 80% at 4 hours, while KS-22-α1 and KS-22-α1 powder type + silver salt showed 95% or more, and from day 1 onwards, showed an inhibition rate of 99% or more, compared to a range of 97-99% for Control Treatment 1.

[0162] (Isovaleric acid) Isovaleric acid also showed a similar trend to valeric acid, with the control showing 0.33 ppm after 4 hours and around 1.1 ppm after the first day. Control treatment 1 showed 0.04 ppm after 4 hours and 0.01 ppm or less after the first day, while KS-22-α1 and KS-22-α1 powder type + silver salt showed 0.01 ppm or less after the fourth hour. The inhibition rate also showed a similar trend to n-valeric acid.

[0163] The results of the measurements of these three fatty acids showed that KS-22-α1 rapidly suppressed the volatilization of gases that cause acidic stool odors in a short period of time. Furthermore, it can be said that the volatilization of these components was suppressed for two weeks, maintaining a higher level than conventional products.

[0164] (Indole, skatole) Indole and skatole are chemical compounds with different properties and are typical components of fecal odor. The volatilization concentration of indole also tended to increase gradually, with indole reaching 0.017 ppm initially and 0.090 ppm after two weeks. Skatole also showed 0.005 ppm initially and 0.029 ppm after two weeks.

[0165] Although the concentrations were lower with Control Treatment 1 than with the control, indole was 0.010-0.027 ppm and skatole was 0.004-0.016 ppm, showing a gradual trend of increasing concentrations until the first or second week. With KS-22-α1 and KS-22-α1 powder type + silver salt, the volatile concentrations were clearly lower than with the control and Control Treatment 1, with indole at 0.002-0.010 ppm and skatole at 0.001-0.003 ppm.

[0166] In terms of the inhibition rate, indole showed 40% initially and 60-70% after the first day, while skatole showed large fluctuations but remained between 10-50%, indicating a low inhibitory effect. Skatole in particular is a substance that is considered to be a representative of fecal odor, and the results showed that the volatilization inhibition rate for this substance was insufficient.

[0167] On the other hand, in the case of KS-22-α1 and KS-22-α1 powder type + silver salt, both indole and skatole showed approximately 75% at 4 hours, and then increased slightly, reaching 80-90% for KS-22-α1 and over 90% for KS-22-α1 powder type + silver salt.

[0168] Control treatment 1 had a low inhibitory effect on indole and skatole, and in some cases showed volatilization concentrations higher than those of the control, but KS-22-α1 was able to inhibit them at a high level, generally above 80%, which is thought to reduce the odor intensity caused by indole and skatole by about one level.

[0169]

[0170]

[0171]

[0172]

[0173]

[0174]

[0175]

[0176]

[0177]

[0178]

[0179] It was clear that Control Treatment Agent 1 was effective against fatty acids contained in stool odor, but was less effective against alkaline compounds such as ammonia, indole, and skatole, and it was shown that, depending on the situation, there is a possibility that the amount of odorous substances may increase compared to when Control Treatment Agent 1 is not used.

[0180] The results of measuring the concentrations of n-butyric acid, n-valeric acid, isovaleric acid, indole, and skatole, as well as the inhibition rates relative to the odorant control after 24 hours and one week, are summarized below.

[0181]

[0182] To summarize the above test results, the basic performance of the treatment agent containing slaked lime and pepper was such that a significant improvement was achieved in the target volatile concentration of indole and skatole, and further improvement was observed for fatty acids, which also performed well in the control treatment agent 1.

[0183] Next, to confirm the effect of combining slaked lime and pepper, the number of constituent ingredients was reduced and an investigation was carried out.

[0184] Specifically, the following ingredients were added to the control (i), and the comfort level was determined in the same manner as above.

[0185]

[0186]

[0187]

[0188]

[0189]

[0190]

[0191] As can be seen from the above results, the combination of slaked lime and pepper shows a significant or heterogeneous effect.

[0192] Next, the antibacterial / sterilizing effects of Samples A to C were evaluated below.

[0193] <Evaluation of Antibacterial / Bactericidal Effects> (Sample Preparation) Samples A to C were prepared by uniformly mixing the components of the following composition.

[0194]

[0195]

[0196] (Bacterial species) The following three species of bacteria were selected for measurement of antibacterial / bactericidal effects: Escherichia coli, Vibrio cholerae, and Clostridioides difficile. Escherichia coli is a facultatively anaerobic, Gram-negative bacillus, and is the most frequently detected bacterium in hospital laboratories. Vibrio cholerae, like Escherichia coli, is a Gram-negative bacillus, but is a species that is often feared to spread in low-sanitary environments during disasters. Clostridioides difficile is a Gram-positive bacillus that is a representative causative bacterium of opportunistic infections. It forms spores and is resistant to various sterilization and disinfection methods, and therefore requires special attention in hospital infection control. The following five strains belonging to these three species were subjected to measurement.

[0197] - Escherichia coli: Standard strain ATCC25922 Clinical isolate (2022 1-1110, blood isolate) - Vibrio cholerae: Clinical isolate 1 (2009 7-1320, pus isolate) Clinical isolate 2 (2010 8-1057, fecal isolate) - Spore-forming bacteria (Clostridioides difficile): Clinical isolate (2021 8-68, fecal isolate) Note that the above clinical isolates were obtained from unspecified patients and maintained at the MedTech Link Center of Chiba University Hospital. The above clinical isolates are not novel microorganisms. Therefore, they have not been deposited at a depository institution. However, the applicant is willing to provide the clinically isolated bacteria according to the present invention to a third party if it falls under any of the items of Article 27-3 of the Enforcement Regulations of the Patent Act of Japan, provided that the relevant laws and regulations are observed.

[0198] (Bacterial sample preparation) - Spore-forming bacteria (Clostridioides difficile): For spore-forming bacteria (Clostridioides difficile), sterilized saline was autoclaved, and a test bacterial solution of McFarland turbidimetric method (Mcf) 0.5 was prepared using sterilized saline from which dissolved oxygen had been removed. Next, 30 mg of each of the samples A to C prepared above was placed in a 1.5 mL microtube, and then 1 mL of the test bacterial solution was added and mixed. The test bacterial solution was prepared by leaving the test bacterial solution at room temperature (25 ° C; the same applies below) for the reaction time (30 minutes or 24 hours) shown in Table 45 below. Note that the McFarland turbidimetric method (Mcf) is a method for estimating the viable bacterial concentration of a bacterial solution from turbidity, and McF 0.5 is 1 × 10 for spore-forming bacteria. 8 CFU (colony forming unit) corresponds to CFU / mL. In this case, CFU (colony forming unit) is the number of colonies that form when a bacterium is inoculated into a solid medium for growth, and indicates the number of viable microbial cells contained in the inoculated microorganism.

[0199] After standing at room temperature for a predetermined time (30 minutes or 24 hours), the test bacterial solution was mixed again and centrifuged at 3,000 rpm for 10 minutes to separate the supernatant. 10 μL of this supernatant was collected with a micropipette and inoculated into a medium by a semi-quantitative method using a platinum loop. The medium was then incubated at 35°C for 48 hours in an anaerobic atmosphere (H2 [10%]: N 2 [10%]: CO 2 The control bacterial solution to which no sample was added was prepared by collecting 10 μL with a micropipette immediately after preparation of the test bacterial solution, inoculating the medium by a semi-quantitative method using a platinum loop, and culturing the control bacterial solution in an anaerobic atmosphere (H 2 [10%]: N 2 [10%]: CO 2 The culture was performed in Anaerobic Culture Medium (RS medium) (manufactured by Nippon Becton Dickinson Co., Ltd.) for 48 hours. Each test was performed in duplicate.

[0200] When the test bacterial solution was incubated with Sample A for 30 minutes and compared with the control bacterial solution, a decrease in the number of bacteria was observed (see Figure 1). Therefore, in order to quantify the decrease in the number of bacteria, a separate incubation measurement for calculating the number of bacteria was carried out using the method described below.

[0201] In the same manner as above, a control bacterial solution immediately after preparation, as well as control and test bacterial solutions left at room temperature for 30 minutes and 24 hours, were prepared. These bacterial solutions were mixed again and then centrifuged at 3,000 rpm for 10 minutes to separate the supernatant. A 10-fold dilution series (diluted bacterial solution) was prepared from this supernatant using sterilized saline that had been autoclaved in advance in the same manner as above, and 100 μL of each diluted bacterial solution was taken from 1 mL and inoculated into a medium (Nippon Becton Dickinson Co., Ltd., Anaero Columbia RS blood agar medium (RS medium)) and incubated at 35 ° C for 4 days in an anaerobic atmosphere (H 2 [10%]: N 2 [10%]: CO 2 The samples were cultured (anaerobic culture) in a 0% CO2 (80%) medium. After 4 days of culture, the number of viable bacteria in each sample was evaluated based on the number of colonies visually observed on each medium. The results are shown in Table 45 below. In Table 45, the reaction time of 0 minutes indicates the time immediately after preparation of the bacterial solution (no sample reaction or centrifugation had been performed). The numbers in parentheses indicate the ratio of the number of bacteria obtained after the reaction of each sample to the number of bacteria obtained from the control.

[0202] Escherichia coli and Vibrio cholerae: For Escherichia coli and Vibrio cholerae, a test bacterial solution with McFarland turbidimetric (Mcf) of 0.5 was prepared using sterile saline. Next, 30 mg of each of the samples A to C prepared above was placed in a 1.5 mL microtube, and 1 mL of each test bacterial solution was added and mixed. The mixture was left to stand at room temperature for the reaction time (30 minutes or 24 hours) shown in Table 45 below to prepare a test bacterial solution. The McFarland turbidimetric (Mcf) method is a method for estimating the viable cell concentration of a bacterial solution from turbidity, and a McF of 0.5 is 1 x 10 for E. coli. 8 CFU / ml and 1 × 10 Vibrio cholerae 7 In this case, CFU (colony forming unit) is the number of colonies that form when a bacterium is inoculated into a solid medium for growth, and indicates the number of viable microbial cells contained in the inoculated microorganism.

[0203] After standing at room temperature for a predetermined time (30 minutes or 24 hours), the test bacterial solution was mixed again and centrifuged at 3,000 rpm for 10 minutes to separate the supernatant. 10 μL of this supernatant was collected with a micropipette and inoculated into a medium using a semi-quantitative method using a platinum loop. The medium was then cultured at 35 ° C in an air atmosphere (atmospheric culture) for the period shown in Table A below (1 day or 4 days). For the control bacterial solution to which no sample was added, 10 μL was collected with a micropipette immediately after preparation of the test bacterial solution, inoculated into the medium, and cultured at 35 ° C in an air atmosphere (atmospheric culture) for 1 day or 4 days. Escherichia coli was cultured in Poremedia (registered trademark) Drigalski modified medium (BTB medium) (manufactured by Eiken Chemical Co., Ltd.), and Vibrio cholerae was cultured in Trypticase™ soy 5% sheep blood agar medium (BA medium) (manufactured by Nippon Becton Dickinson Co., Ltd.). Each test was performed in duplicate.

[0204] After culturing for a predetermined period (1 or 4 days), the number of colonies confirmed visually was examined. The results are shown in Table 46 below. In Table 46 below, "-" indicates that no growth was observed.

[0205]

[0206] As shown in Table 46 above, for spore-forming bacteria, the reduction in bacterial count compared to the control was only 25% to 82% after 30 minutes of exposure to each sample, and a 68% to 99.94% reduction in bacterial count was confirmed after 24 hours of exposure. This result is considered to indicate a higher antibacterial effect than the samples of the current product. In contrast, no bacterial growth was observed at all for E. coli and V. cholerae after 30 minutes of exposure to the reagent. Of these, in the case of E. coli, Mcf 0.5 = 10 8 Since the number of CFU / mL is 10 6 CFU / mL, but since no bacterial growth was observed after culturing, it is believed that the number of bacteria has decreased to at least 10 6 It is believed that the control effect is more than 99.9999%. In addition, for Vibrio cholerae, Mcf 0.5 = 10 7 CFU / mL, so a maximum of 10 5 CFU / mL, but as with E. coli, no growth was observed after cultivation. 5 It is believed that the control effect is at least 99.999% (CFU / mL). In the case of both E. coli and V. cholerae, no bacterial growth was observed even after 4 days of culture, so it is believed that all of the bacteria were killed.

[0207] The difference in the results between the spore-forming bacteria (C. difficile) and Escherichia coli (E. coli) or Vibrio cholerae (V. cholerae) is presumably due mainly to the influence of the spores possessed by the spore-forming bacteria. Considering that sterilization with disinfectants such as alcohol or benzalkonium chloride is ineffective against spores, and that spores cannot be completely inactivated even by boiling at 100°C (i.e., it is difficult to completely kill them), Sample A of the present invention is expected to be clinically useful.

[0208] In this study, the reagent was applied to the bacterial solution, so it was suspended in the sample. Therefore, the centrifuged supernatant was used for the culture measurement. This centrifugation procedure reduced the bacterial count to approximately 1 / 100 for E. coli, approximately 1 / 10-1 / 100 for V. cholerae, and approximately 1 / 500 for C. difficile. Furthermore, leaving the bacterial solution undisturbed for 24 hours reduced the bacterial count to approximately 1 / 1-1 / 10 for E. coli, approximately 1 / 10-1 / 100 for V. cholerae, and approximately 1 / 10 for C. difficile.

[0209] Although the embodiments of the present invention have been described in detail, it is clear that this is by way of illustration and example only and not of limitation, and that the scope of the present invention should be interpreted by the appended claims.

[0210] The present invention encompasses the following aspects and configurations.

[0211] 1. A treatment agent for treating wastewater, comprising slaked lime and pepper.

[0212] 2. The treatment according to claim 1, wherein the pepper is not in the form of a piperine extract.

[0213] 3. The treatment agent according to 1. or 2., which contains a water-absorbing polymer.

[0214] 4. The treatment agent according to any one of 1. to 3., wherein the content (mass%) of the slaked lime is 0.1 to 40% by mass and the content (mass%) of the pepper is 0.05 to 30% by mass.

[0215] 5. The treatment agent according to any one of 1. to 4., which contains zinc oxide.

[0216] 6. The treatment agent according to any one of 1. to 5., which contains at least one selected from the group consisting of lignin, bentonite, and zeolite.

[0217] 7. The treatment agent according to any one of 1. to 6., further comprising humic acid.

[0218] 8. The treatment agent according to any one of 1. to 7., wherein the waste liquid contains excrement, blood, vomit, or bodily fluids discharged from humans or animals.

[0219] 9. The treatment agent according to any one of 1. to 8., wherein the waste liquid contains at least one of indole and skatole as a malodorous component.

[0220] 10. The treatment agent according to any one of 1. to 9., which is used to suppress or inhibit spore germination or proliferation of spore-forming bacteria.

[0221] 11. The treatment agent according to 10., wherein the spore-forming bacterium is Clostridioides difficile.

[0222] 12. A method for suppressing or inhibiting spore germination or proliferation of spore-forming bacteria, comprising contacting a waste liquid with the treating agent according to any one of 1. to 11.

[0223] The above is the description of the first invention. Next, the second invention will be described.

[0224] <Second Invention> [Title of Invention] Waste liquid treatment device and downstream side waste liquid treatment device [Technical Field] The present invention relates to a waste liquid treatment device and a downstream side waste liquid treatment device.

[0225] [Background Art] Proper disposal of excrement is important for maintaining a hygienic and comfortable environment, but this can be difficult in a variety of situations and places, such as evacuation sites where flush toilets cannot be used during emergency disasters, areas with insufficient infrastructure such as mountainous or coastal areas, rooms of people requiring care who cannot go to the toilet on their own, ostomy pouches that receive feces from patients who have undergone stoma creation surgery such as colostomy, and hospital operating rooms and endoscopy rooms.

[0226] For example, in an endoscopy room, the endoscope is divided into upper examinations, which are performed through the mouth or nose to examine the stomach, etc., and lower examinations, which are performed through the anus to examine the rectum, large intestine, and small intestine. Both upper and lower examinations involve suction of bodily fluids, and in some cases washing with water during the examination, so waste liquid containing excrement, blood, and bodily fluids is discharged. The waste liquid containing bodily fluids generated in this way is sent for waste disposal.

[0227] Patent Document 1 proposes a disposable collection container made of synthetic resin as one method of waste disposal.

[0228] However, even when disposable collection containers are used, there is a problem that waste liquid inside the container may leak due to damage to the container when transporting the collected container to a processing facility, which not only poses a hygiene problem but can also be undesirable for the person who will ultimately process the waste.

[0229] Therefore, in Patent Document 2, in order to provide a treatment container for waste liquid containing body fluids that can easily incinerate waste liquid containing body fluids stored in the container and that is excellent in terms of hygiene and safety, the treatment container for waste liquid containing body fluids is characterized in that the treatment container for waste liquid containing body fluids has a sealed collection container made of synthetic resin for storing waste liquid containing body fluids, and is provided with a waste liquid inlet pipe and an exhaust pipe for exhausting air from the collection container at the top of the collection container, and the treatment container for waste liquid containing body fluids is characterized in that a coagulant container containing a coagulant made entirely or mainly of a high molecular weight absorbent polymer is provided at the top of the collection container, and an injection means is provided for injecting the coagulant in the coagulant container into the waste liquid stored in the collection container.

[0230] [Prior art documents] [Patent documents] [Patent document 1] JP-A-51-48589 [Patent document 2] JP-A-02-157083

[0231] In Patent Document 2, a tube is connected to a container for storing body fluid, the body fluid is collected in the container by suction, and the body fluid is brought into contact with a treatment agent containing a polymeric water absorbent inside the container to coagulate the body fluid.

[0232] However, the inventors have found that such a configuration may cause the solidified material in the container to be attracted to the downstream pipe and block the downstream pipe, which may occur not only when an endoscope is used in a medical setting, but also when a device such as a manual pump is used at a disaster site.

[0233] Therefore, the challenge is to provide a new technology for waste liquid treatment that can prevent body fluids that have come into contact with the treatment agent from blocking the path of the tubular member connected to the container when a treatment agent has been placed in the container in advance and a tubular member is connected to the container to collect body fluids in the container.

[0234] One aspect of the present invention is a waste liquid treatment device. The waste liquid treatment device includes a container, a lid, a partition member, and an excrement treatment agent. The container has an internal space capable of containing body fluids contained in or excreted by humans, and an opening through which body fluids can be introduced into the internal space by suction. The lid can be attached to the container to close the opening of the container, and has an inlet through which body fluids can flow into the internal space by suction. The partition member is disposed in the internal space and is configured to divide the internal space into a first internal space proximal to the opening and a second internal space located distal to the opening relative to the first internal space. The excrement treatment agent is disposed in the second internal space of the container and is configured to convert the body fluid into a solid swelling substance upon contact with the body fluid. The partition member is configured to allow bodily fluids flowing from the inlet portion into the internal space to flow between the first internal space and the second internal space, and to block the flow of swelling substances produced when the bodily fluids flowing into the second internal space come into contact with the excrement treatment agent into the first internal space.

[0235] Another aspect of the present invention is a downstream waste liquid treatment device that includes a second container, a second lid, the excrement treatment agent, and a displacement member and is connectable to the waste liquid treatment device via a tubular member. The second container has the internal space and the opening. The second lid is attachable to the second container so as to close the opening of the second container and includes the inlet portion and a second outlet portion through which gas discharged from the internal space by suction can flow downstream. The excrement treatment agent is disposed in the internal space of the second container and converts the body fluid into a swelling substance by contacting the body fluid. The displacement member blocks the flow of the body fluid and the swelling substance downstream when the swelling substance generated by contact of the excrement treatment agent with the body fluid reaches a predetermined height in the internal space.

[0236] According to one aspect of the present invention, when a treatment agent is placed in a collection container in advance and a tubular member is connected to the container to collect body fluids in the container, the body fluids that have come into contact with the treatment agent can be prevented from blocking the path of the tubular member connected to the container.

[0237] BRIEF DESCRIPTION OF THE DRAWINGS FIG. 2 is a schematic perspective view showing a waste liquid treatment device and a downstream waste liquid treatment device according to an embodiment.

[0238] [Figure 3] A front view of Figure 2.

[0239] 4 is an exploded perspective view showing the configuration of the waste liquid treatment device shown in FIG. 2. [FIG.

[0240] 5 is a cross-sectional view taken along the height direction, showing the inside of the waste liquid treatment device shown in FIG.

[0241] 6 is a perspective view showing a lid and a partition member that constitute the waste liquid treatment device shown in FIG. 3. FIG.

[0242] 7 is a perspective view showing the lid and the partition member cut at a position different from that in FIG. 6.

[0023] FIG.

[0243] FIG. 8 is an exploded perspective view showing the configuration of the partition member.

[0244] FIG. 9 is a plan view showing a partition member.

[0245] 10 is an exploded perspective view showing the configuration of the downstream waste liquid treatment device shown in FIG. 2. [FIG.

[0246] FIG. 11 is a cross-sectional view taken along the height direction showing the inside of the downstream waste liquid treatment device.

[0247] FIG. 12 is a perspective view showing the cover, connecting member, and mounting member that constitute the downstream waste liquid treatment device, with the cover cut away.

[0248] 13 is an enlarged view of FIG. 10 showing the lid, the connecting member, the mounting member, and the displacement member, and showing the state where gas or the like used for suction flows through the inside of the mounting member.

[0249] 14 is an enlarged view showing a state in which the position of the displacement member in FIG. 12 is different from that in FIG. 12.

[0250] FIG. 15 is an exploded perspective view of a waste liquid treatment device showing a modified example of FIG.

[0251] 16 is an exploded perspective view showing a downstream waste liquid processing device according to a modified example of FIG. 9.

[0252] FIG. 17 is a perspective view showing a partition member according to a modified example.

[0253] [Figure 18] An exploded perspective view of Figure 17.

[0254] [Figure 19] A plan view of Figure 17.

[0255] FIG. 20 is a perspective view showing a partition member according to a modified example.

[0256] FIG. 21 is a diagram showing a modification of FIG. 13.

[0257] FIG. 22 is a diagram showing a modification of FIG. 14.

[0258] FIG. 23 is a perspective view showing a modification of FIG. 2.

[0259] FIG. 24 is an exploded perspective view showing a capture assembly attached to a waste liquid processing tool according to a modified example.

[0260] FIG. 25 shows the inside of the capture assembly.

[0261] [Mode for Carrying Out the Invention] Hereinafter, a mode for carrying out the second invention will be described in detail with reference to the drawings. The embodiments shown here are provided as examples to embody the technical idea of ​​the present invention and are not intended to limit the present invention. Furthermore, all other modes, examples, and operational techniques that can be conceived by those skilled in the art without departing from the gist of the present invention are included in the scope and gist of the present invention, as well as in the scope of the inventions described in the claims and their equivalents.

[0262] Furthermore, for the convenience of illustration and ease of understanding, the drawings attached to this specification may be represented schematically with the scale, aspect ratio, shape, etc. appropriately changed from the actual product, but these are merely examples and do not limit the interpretation of the present invention.

[0263] In the following description, ordinal numbers such as "first" and "second" are used, but unless otherwise specified, these are used for convenience and do not stipulate any particular order.

[0264] For ease of explanation, coordinate systems are shown in the drawings. The Cartesian coordinates XY are planes parallel to the plane on which the waste liquid treatment tool 100 or the downstream waste liquid treatment tool 100a is placed, and are conveniently referred to as the planar direction XY. The Cartesian coordinate Z is a direction perpendicular to the planar direction XY, and is conveniently referred to as the height direction Z. The cylindrical coordinate r indicates a radial or radiating direction from the center of either the container 10, 10a or the lid 30, 30a, and is referred to as the radial direction r. The cylindrical coordinate θ indicates a circumferential or angular direction of the container 10, and is conveniently referred to as the circumferential direction θ.

[0265] The waste liquid treatment device 100 and downstream-side waste liquid treatment device 100a according to the embodiment will be described below with reference to Figures 2 to 14. Figure 2 is a schematic perspective view showing the waste liquid treatment device 100 and downstream-side waste liquid treatment device 100a according to the embodiment. Figure 3 is a front view of Figure 2. Figure 4 is an exploded perspective view showing the configuration of the waste liquid treatment device 100 according to Figure 2. Figure 5 is a cross-sectional view along the height direction Z showing the interior of the waste liquid treatment device 100. Figure 6 is a perspective view showing the lid portion 30 and partition member 40 that constitute the waste liquid treatment device 100 according to Figure 3. Figure 7 is a perspective view showing the lid portion 30 and partition member 40 cut at a position different from that shown in Figure 6. Figure 8 is an exploded perspective view showing the configuration of the partition member 40. Figure 9 is a plan view showing the partition member 40.

[0266] Figure 10 is an exploded perspective view showing the configuration of the downstream waste liquid treatment device 100a. Figure 11 is a cross-sectional view along the height direction Z showing the interior of the downstream waste liquid treatment device 100a. Figure 12 is a perspective view showing the lid portion 30a, connecting member 50, and mounting member 60 that constitute the downstream waste liquid treatment device 100a. Note that for convenience of explanation, Figures 6, 7, and 12 show the lid portions 30 and 30a partially cut away. Figure 13 is an enlarged view of Figure 11 showing the connecting member 50, mounting member 60, and displacement member 70, illustrating the flow of gas or the like used for suction inside the connecting member 50. Figure 14 is an enlarged view showing the displacement member 70 in Figure 13 in a different position from that in Figure 13.

[0267] The waste liquid treatment device 100 and the downstream-side waste liquid treatment device 100a according to this embodiment can be used when treating body fluids discharged from patients using an endoscope or the like in medical institutions such as hospitals, or when treating body fluids discharged from people living in disaster-stricken areas or the like. In Figures 2 and 3, two waste liquid treatment devices 100 and one downstream-side waste liquid treatment device 100a are provided as examples, and are connected to each other by a tubular member T. The waste liquid treatment device 100 and the downstream-side waste liquid treatment device 100a will now be described.

[0268] <Waste Liquid Treatment Device> The waste liquid treatment device 100, generally described with reference to Figure 4 etc., comprises a container 10, an excrement treatment agent 20, a lid 30, a partition member 40, and a connecting member 50. Details will be described below.

[0269] <Container> As shown in Figure 5, the container 10 is configured to have an internal space 12 capable of containing bodily fluids contained in or excreted from a human being, and an opening 11 through which bodily fluids can be introduced into the internal space 12. The specific configuration of the container 10 is not particularly limited as long as the container 10 contains bodily fluids and is not damaged when the internal pressure is reduced by a pump or the like. The upper part of the container 10 may be provided with a fastening portion (fastening shape) such as a male thread that engages with a thread provided on a flange portion 32 of the lid portion 30, which will be described later. The container 10 can be made of materials such as polyethylene, polypropylene, polycarbonate, and thermoplastic resins such as ABS (acrylonitrile butadiene styrene), but the thickness, shape, etc. of the container 10 are not particularly limited as long as they are significantly suitable for containing bodily fluids.

[0270] <Excrement Treatment Agent> The excrement treatment agent 20 constitutes the internal space 12 of the container 10 and is disposed in a second internal space 14 (described later), and is configured so that it can change body fluid into a solid swelling substance w upon contact with the body fluid. In this embodiment, the excrement treatment agent 20 is configured in a block form as shown in Fig. 5 etc., and is configured so that when it is disposed in the internal space 12 of the container 10, a visually visible gap can be formed between adjacent excrement treatment agents 20. This configuration prevents excrement treatment agents 20 located lower in the container 10 from being prevented from contacting the body fluid due to excrement treatment agents 20 located higher that have swelled earlier when body fluid is introduced into the internal space 12 and the excrement treatment agents 20 come into contact with the body fluid and swell.

[0271] The excrement treating agent 20 contains a water-absorbing polymer. By including a water-absorbing polymer, moisture and the like in the object to be treated are absorbed, and the treated object is more likely to solidify (become jelly-like). In this specification, "water-absorbing polymer (water-absorbing resin)" refers to a polymer gelling agent having a water swelling capacity (CRC) defined by ERT441.2-02 of 5 g / g or more and a water-soluble component (Ext) defined by ERT470.2-02 of 50 mass% or less.

[0272] In one embodiment of the present invention, specific examples of water-absorbent polymers include starch-based water-absorbent polymers such as starch-acrylonitrile graft polymer hydrolysates and starch-acrylic acid graft polymers; cellulose-based water-absorbent polymers such as cellulose-acrylonitrile graft polymers and cellulose-styrene sulfonic acid graft copolymers; polysaccharide-based water-absorbent polymers such as pectin; protein-based water-absorbent polymers such as collagen; polyvinyl alcohol-based water-absorbent polymers such as polyvinyl alcohol crosslinked polymers; acrylic-based water-absorbent polymers such as sodium polyacrylate crosslinked products, acrylic acid polymer partial sodium salt crosslinked products, and sodium acrylate-vinyl alcohol copolymers; maleic anhydride-based water-absorbent polymers; vinylpyrrolidone-based water-absorbent polymers; and polyether-based water-absorbent polymers such as polyethylene glycol diacrylate crosslinked polymers. These water-absorbent polymers may be used alone or in combination of two or more. Furthermore, these water-absorbent polymers may be synthesized or commercially available products may be used. Examples of commercially available products include AQUAKEEP (registered trademark) SA (manufactured by Sumitomo Seika Chemicals Co., Ltd.), AQUALIC (registered trademark) CA (manufactured by Nippon Shokubai Co., Ltd.), SANFRESH (ST-250, ST-100, ST-573), AQUAPEARL (manufactured by Sandia Polymers Co., Ltd.), HYMOSUB HS-960 (manufactured by HYMO Corporation), and EF POLYMER (manufactured by EF Polymer Private Limited).

[0273] In one embodiment of the present invention, the water-absorbing polymer may be carboxymethyl cellulose. Carboxymethyl cellulose is a cellulose derivative, and has carboxymethyl groups (-CH) attached to some of the hydroxy groups of the gluconopyranose monomers that constitute the cellulose skeleton. 2 The carboxymethyl cellulose is a thickener having a high affinity for water and forming a highly viscous gel when mixed with water. In the present invention, the thickening of the treatment agent enhances the malodor suppression effect and allows the suppression effect to be maintained.

[0274] According to one embodiment of the present invention, the average particle size of the water-absorbing polymer is 1 to 1200 μm, 50 to 1100 μm, 10 to 1000 μm, 80 to 850 μm, 100 to 600 μm, 150 to 500 μm, or 200 to 400 μm.

[0275] According to one embodiment of the present invention, the processing agent may be granulated using a binder such as water, PVA, cellulose, water-soluble cellulose, water-soluble carboxymethyl cellulose, or sodium alginate. That is, according to one embodiment of the present invention, the processing agent is a bulk processing agent. Furthermore, the processing agent according to one embodiment of the present invention may be in the form of a granular processing agent or a bulk processing agent using the techniques of JP 2013-6137 A or JP 2011 / 162244 A. According to one embodiment of the present invention, the processing agent includes a lubricant. The lubricant is used when preparing the bulk processing agent, particularly to facilitate smooth feeding into the die of the tablet press. Therefore, the type of lubricant may be appropriately selected from conventionally known lubricants or may be used in combination. For example, ester-based, silicon-based, stearic acid ester, calcium stearate, potassium stearate, calcium, zinc, etc. may be used.

[0276] According to one embodiment of the present invention, the average diameter of the treatment agent is 3 to 100 mm, or 5 to 50 mm. In this specification, unless otherwise specified, "average diameter" refers to the average value obtained by arbitrarily selecting a statistically reliable number of particles (e.g., 10, 100, 200, 300, or 1,000 particles), measuring the longest particle diameter for each particle with a vernier caliper, and arithmetically averaging the measured diameters. The excrement treatment agent 20 is not limited to a lump or granular form, and may also be in powder form. In this case, according to one embodiment, the average particle diameter of the treatment agent is 10 μm or more, 30 μm or more, 50 μm or more, 100 μm or more, 300 μm or more, 500 μm or more, 700 μm or more, 1 mm or more, or 2 mm or more. According to one embodiment, the average particle size of the treatment agent is 3 mm or less, 2 mm or less, 1000 μm or less, 700 μm or less, 500 μm or less, 300 μm or less, 100 μm or less, 50 μm or less, or 30 μm or less. According to one embodiment, the average particle size is 10 μm to 30 μm, 30 μm to 50 μm, 50 μm to 100 μm, 100 μm to 300 μm, 300 μm to 500 μm, 500 μm to 700 to 1000 μm, 1 mm to 2 mm, or 2 mm to 3 mm.

[0277] <Lid> The lid 30 is configured to be attachable to the container 10 so as to close the opening 11 of the container 10. By configuring it in this manner, the user can enclose the internal space 12 of the container 10 when the excrement treating agent 20 and the partition member 40 are attached to the internal space 12 of the container 10.

[0278] As shown in Figure 5 and other figures, the lid 30 includes a covering portion 31, a flange portion 32, a connecting portion 33 (corresponding to the inlet portion), a connecting portion 34 (corresponding to the outlet portion), and an engaging recess 35. The covering portion 31 is configured to cover the opening 11 of the container 10 when the lid 30 is attached to the container 10. The covering portion 31 is formed in a shape with a concave step in the approximate center, excluding the shapes of the connecting portions 33 and 34, but the specific shape is not limited to the above shape and may be a simple flat surface as long as it can cover the opening of the container 10 when attached to the container 10.

[0279] The flange portion 32 is formed so as to rise down from the outer peripheral edge of the covering portion 31 in the height direction Z. The flange portion 32 is configured to cover the upper outer surface of the container 10 when attached to the container 10. The flange portion 32 is configured to have a shape such as an internal thread that can be threadedly engaged with a threaded portion provided on the outer surface of the container 10. The specific shape of the fastening portion (fastening shape) such as the internal thread provided on the flange portion 32 is not particularly limited, as long as it can generate a suction force in the internal space 12 when the lid portion 30 is attached to the container 10, or as long as the generated suction force is not extremely reduced due to unintended gas leakage or the like.

[0280] The connecting parts 33, 34 are provided to pass through the inside and outside of the lid part 30, and are configured to allow attachment of a coupling member 50 that can connect a tubular member T that circulates body fluids into the internal space 12 of the container 10 by suction. By connecting the coupling member 50 to the tubular member T, the connecting part 33 functions as an inflow part that allows body fluids and the like to circulate into the internal space 12 by suction, and the connecting part 34 functions as an outflow part that allows at least one of gas and body fluids discharged from the internal space 12 by suction to flow downstream.

[0281] The engaging recesses 35 are configured to be engageable with the engaging protrusions p3 so as to position the partition member 40 in the internal space 12 when the lid 30 is attached to the container 10. The engaging recesses 35 are configured to be provided on the side of the internal space 12 when the lid 30 is attached to the container 10. In this embodiment, the engaging recesses 35 are configured to have two cylindrical recesses that can engage with the engaging protrusions p3 of the partition member 40 (see FIG. 6). However, the shape and number of engaging shapes are not limited to those described above as long as the partition member can be positioned relative to the lid.

[0282] <Partition Member> As shown in Fig. 5 and other figures, the partition member 40 is disposed in the internal space 12 and is configured to divide the internal space 12 into a first internal space 13 located proximal to the opening 11 and a second internal space 14 located distal to the opening 11 relative to the first internal space 13. The partition member 40 allows bodily fluid flowing into the internal space 12 from the connection portion 33 to flow between the first internal space 13 and the second internal space 14. The partition member 40 is also configured to block the flow of a swelling substance w (see the two-dot chain line in Fig. 5 ) generated when the bodily fluid that has flowed into the second internal space 14 comes into contact with the excrement treating agent 20 into the first internal space 13.

[0283] The partition member 40 is disposed in the internal space 12 closer to the opening 11 than the excrement treating agent 20. As shown in Fig. 8, the partition member 40 includes a first member 41 and a second member 42. The first member 41 and the second member 42 are configured to have a small (thin) thickness in the height direction Z, and are laminated in the thickness direction to form an integrated structure.

[0284] The first member 41 allows bodily fluids to flow between the first internal space 13 and the second internal space 14 .

[0285] In this embodiment, the second members 42 are configured as a pair so as to sandwich the first member 41. As shown in Fig. 8 etc., the second members 42 include a covering portion p1, a hole portion p2, an engaging protrusion p3, a first wall portion p4, and a second wall portion p5.

[0286] The covering portion p1 is configured as a portion that partially covers one side of the first member 41 without exposing it. The hole portion p2 is configured as a portion that exposes one side of the first member 41. In this embodiment, the covering portion p1 is provided relatively outside in the radial direction r of the partition member 40, and the hole portion p2 is provided relatively inside in the radial direction r of the partition member 40. Note that the specific shape of the hole portion p2 is not limited to the shape shown in the figure, as long as it allows body fluids and the like to flow from the first internal space 13 to the second internal space 14 and inhibits the movement of the swelling substance w from the second internal space 14 to the first internal space 13.

[0287] As described above, the engaging protrusion p3 is configured to be engageable with the engaging recess 35 of the lid portion 30. In this embodiment, two engaging protrusions p3 are provided, similar to the engaging recess 35 of the lid portion 30, but as described above, the specific number does not have to be two, and the shape may also be a shape other than that shown in Figure 8, etc. Also, in Figure 6, the engaging recess 35 is provided on the lid portion 30 and the engaging protrusion p3 is provided on the partition member 40, but as long as the two can be engaged with each other, the opposite may be true, with a protrusion provided on the lid portion and a recess provided on the partition member.

[0288] The first wall portion p4 is arranged in the first internal space 13 when the partition member 40 is installed in the internal space 12, and is configured to be arranged between the connecting portion 33 and the connecting portion 34 and adjacent to the connecting portion 34. This makes it possible to prevent or suppress bodily fluid that has flowed into the internal space 12 from the connecting portion 33 from flowing downstream through the flow path of the connecting member 50 attached to the connecting portion 34 as shown by arrow r1 in Fig. 7 without flowing into the second internal space 14 as shown by arrow r2 in Fig. 7.

[0289] The second wall portion p5 is provided on or near the outer peripheral edge of the covering portion p1. The second wall portion p5 is configured to be disposed adjacent to the connecting portion 33 in the first internal space 13 when the partition member 40 is installed in the internal space 12. Although a gap may be formed between the partition member 40 and the container 10 when the partition member 40 is installed in the container 10, the provision of the second wall portion p5 can promote the flow of bodily fluid flowing in from the connecting portion 33 toward locations other than the boundary between the container 10 and the partition member 40. In other words, in this specification, the partition member 40 allows a gap to be formed between the inner wall surface of the container 10 and the outer peripheral edge of the partition member 40.

[0290] The second members 42 are arranged in pairs on the outside so as to sandwich the first member 41. However, if the partition member 40 includes the first member, the first member does not need to be sandwiched by the second member. Furthermore, the same parts are used for the upper and lower second members 42 when the first member 41 is installed in the container 10. However, if the upper second member in the installed state is provided with the first wall portion p4 and the second wall portion p5, the lower second member may not have the first wall portion and the second wall portion. The second member 42 is configured to have higher rigidity than the first member 41.

[0291] Regarding the material of the partition member 40, the first member 41 may include cotton, nonwoven fabric, woven fabric, cotton, paper, etc. The second member 42 may include materials such as polyethylene and polypropylene. The pore size of the first member 41, such as nonwoven fabric, is preferably smaller than the size of the swollen water-absorbent resin. Furthermore, the surface of the partition member 40 facing the first internal space 13 may be subjected to a hydrophilic surface treatment to promote the flow of body fluids flowing into the first internal space 13 into the second internal space 14. The surface of the partition member 40 facing the second internal space 14 may or may not be surface-treated, but it is preferable not to do so.

[0292] Here, we will explain the dimensions of the partition member 40 and related components of the container 10, etc., so that when the swelling substance w is generated in the second internal space 14, it will not flow into the first internal space 13. The radial dimension d1 (see FIG. 5) of the opening 11 of the container 10 in the radial direction r can be configured to be approximately 135 mm. The size of the hole p2 of the first member 41 is preferably smaller than the swelling substance w generated in the second internal space 14 upon contact with the excrement treating agent 20 so that it does not flow into the first internal space 13. The dimensions of each of the multiple hole shapes constituting the hole p2 in the planar direction XY can be set so that the area of ​​the hole p2 in the partition member 40 is 1 to 40% of the area of ​​the covering portion p1 when viewed in the height direction Z, assuming that the hole p2 does not exist. The thickness of the first member 41 and the second member 42 of the partition member 40 (see FIG. 8) can be configured to be approximately 1.4 mm. The excrement treating agent 20 can be configured as a cylinder with a diameter d2 of about 13 mm and a height d3 of 5 to 6 mm (see FIG. 5).

[0293] <Connecting Member> The connecting member 50 is used to connect adjacent waste liquid treatment tools 100 or downstream waste liquid treatment tools 100a to each other via the tubular member T. The connecting member 50 is attached to the connection portions 33, 34 of the lid portion 30, through which body fluid flows in and out of the internal space 12 of the lid portion 30. As shown in Figure 5, the connecting member 50 has an outer portion 51 and an inner portion 52. The connecting member 50 is formed in a hollow cylindrical shape so that, when the lid portion 30 is attached, the connection portion 33 allows body fluid from the upstream side to flow into the internal space 12, and the connection portion 34 allows body fluid located in the internal space 12 of the container 10 to flow downstream.

[0294] The outer portion 51 corresponds to a portion that is disposed on the outside of the internal space 12 when attached to the lid portion 30. In this embodiment, the outer portion 51 is formed to be bent in a substantially L-shape, and is configured to connect to the tubular member T at its tip. Here, the shape of the outer portion is not limited to an L-shape as long as it can connect to the tubular member T, and may be linear, for example.

[0295] The inner portion 52 corresponds to the portion located in the internal space 12 when attached to the lid portion 30. The outer portion 51 and the inner portion 52 form a flow path that allows bodily fluids to flow between the internal space 12 and the outside. The inner portion 52 is provided with a sealing material such as rubber or elastomer at the connection portions 33 and 34 to prevent bodily fluids from leaking from portions other than the flow path. The lower end of the connecting member 50 can abut against a displacement member 70 of the downstream waste liquid treatment tool 100a (described later), and the portion that abuts against the displacement member 70 and becomes part of the flow path is referred to as an open end 53 (see FIG. 13 ). Details will be described later.

[0296] The tubular member T connected to the connecting portions 33, 34 of the lid portion 30 can be made of a known flexible material such as plastic so that it can be connected to the connecting portions 33, 34 in various positions.

[0297] <Downstream Waste Liquid Treatment Device> The downstream waste liquid treatment device 100a is connected to the waste liquid treatment device 100 via a tubular member T and is configured to be located downstream of the waste liquid treatment device 100. As shown in Fig. 10 , the downstream waste liquid treatment device 100a has a container 10a (corresponding to the second container), an excrement treatment agent 20, a lid 30a (corresponding to the second lid), a connecting member 50, an attachment member 60, and a displacement member 70. The container 10a is similar to the container 10 of the waste liquid treatment device 100, and the excrement treatment agent 20 and the connecting member 50 are similar to the respective components of the waste liquid treatment device 100, so detailed description thereof will be omitted.

[0298] <Lid> The lid 30a is configured to be attachable to the container 10a so as to close the opening 11 of the container 10a. As shown in FIG. 11 , the lid 30a includes a covering portion 31, a flange portion 32, a connecting portion 33 (corresponding to the inlet portion), and a connecting portion 34a (corresponding to the second outlet portion). Unlike the lid 30, the lid 30a does not include an engagement recess 35, but like the lid 30, it includes the covering portion 31, the flange portion 32, and the connecting portion 33. Similarly to the connecting portion 34, the connecting portion 34a is configured to allow gas discharged from the internal space 12 by suction to flow downstream while blocking the flow of the swelling substance w, while unlike the connecting portion 34, it does not allow bodily fluids to flow downstream by suction. However, the specific shape of the connecting portion 34a may be configured similarly to the connecting portion 34. Therefore, a description of the covering portion 31, the flange portion 32, and the connecting portions 33 and 34a will be omitted.

[0299] <Mounting Member> Mounting member 60 can be attached to lid portion 30a, and is configured to allow the flow of gas and the like sucked by the pump, and to allow displacement member 70, described below, to be placed on it when the displacement member 70 does not block the flow of swelling substance w. As shown in Figures 12 and 13, mounting member 60 includes a fixing portion 61, a hanging portion 62, a contact portion 63, a flow hole 64, and an insertion hole 65.

[0300] Fixing portion 61 includes a flange having a hole that can be engaged by fitting or the like with a convex shape (not shown) provided on lid portion 30a in order to attach mounting member 60 to lid portion 30a. Fixing portion 61 is configured to include a flange that extends horizontally in the planar direction XY from the end of hanging portion 62.

[0301] Hanging portion 62 is configured to extend downward from the inner end of the flange of fixed portion 61. In this embodiment, hanging portion 62 extends linearly parallel to height direction Z, but may be inclined or curved relative to height direction Z as long as flow holes 64, which will be described later, can be provided.

[0302] The abutment portion 63 holds the displacement member 70 in the vicinity of the connection portion 34a of the internal space 12 when the displacement member 70 does not block the flow path of the connecting member 50 attached to the connection portion 34a. The abutment portion 63 is configured to extend from the lower end of the hanging portion 62 toward the inside of the hanging portion 62 in the planar direction XY, as shown in FIG. 13 etc. The abutment portion 63 is formed to be approximately flat so that it can abut against the fall prevention portion 72 of the displacement member 70. When the displacement member 70 does not at least partially block the open end 53 of the connecting member 50, the displacement member 70 can be placed on the abutment portion 63.

[0303] As shown in FIG. 12 , the communication hole 64 is a notch provided in the hanging portion 62, which allows gas or the like sucked by a pump or the like to circulate between the internal space 12 and the outside through a flow path in the connecting member 50. A plurality of communication holes 64 can be provided on the side surface of the hanging portion 62, particularly in the circumferential direction θ as shown in FIG. 12 . The insertion hole 65 is configured so that an insertion portion 73 of the displacement member 70, which will be described later, is inserted therethrough, thereby allowing the displacement member 70 to move in the height direction Z relative to the mounting member 60. The insertion hole 65 is configured to be provided approximately in the center of the abutting portion 63.

[0304] <Displacement Member> The displacement member 70 is configured to come into contact with and separate from the open end 53 of the connecting member 50 installed in the connection portion 34a. As shown in Fig. 13 , the displacement member 70 includes a blocking portion 71, a fall prevention portion 72, an insertion portion 73, an opposite end portion 74, and a floating portion 75.

[0305] The blocking portion 71 is configured to be able to at least partially block the flow path of the connecting member 50 attached to the connection portion 34a. The blocking portion 71 is configured to include a curved surface provided at the top of the displacement member 70. By abutting this curved surface against the open end 53 of the inner portion 52 of the connecting member 50, it is possible to prevent bodily fluids and swelling substances w that may be present in the internal space 12 from flowing through the flow path of the connecting member 50 attached to the connection portion 34a.

[0306] In this embodiment, the fall prevention portion 72 is provided on the opposite side of the curved surface of the closing portion 71 and is configured to be able to abut against the abutment portion 63 of the mounting member 60. The fall prevention portion 72 is configured so that the mounting member 60 can hold the displacement member 70 at a position near the connection portion 34a in the internal space 12 by abutting against the abutment portion 63. The fall prevention portion 72 can be configured to include a flat surface or the like provided on the opposite side of the curved surface of the closing portion 71.

[0307] The insertion portion 73 can be inserted into the insertion hole 65 of the mounting member 60, and in this embodiment, is configured to include a cylindrical shape. This allows the displacement member 70 to be moved to a position where the blocking portion 71 of the displacement member 70 blocks the flow path of the connecting member 50, or the fall prevention portion 72 to be moved to a position where it abuts against the abutting portion 63. Note that the specific shape of the insertion portion 73 is not limited to the cylindrical shape described above, as long as the blocking portion 71 can be moved to a position where it blocks the flow path of the connecting member 50, or to a position where it does not block the flow path.

[0308] The opposite end portion 74 is configured to be provided on the opposite side of the blocking portion 71 with respect to the insertion portion 73. Due to the shape of the insertion portion 73, the opposite end portion 74 is formed to protrude outward from the center of the insertion portion 73 in the planar direction XY, and can thereby function as a stopper that prevents the displacement member 70 from moving too far upward with respect to the mounting member 60.

[0309] The float portion 75 is located at the lower end in the direction of gravity when installed. When in contact with the surface of the bodily fluid in the internal space 12, it allows the displacement member 70 to float on the surface. Here, although the surface formed by the fluid flowing into the internal space 12 may contain not only bodily fluid but also swelling substances w, hereinafter, it will be referred to simply as the "liquid surface of the bodily fluid." The float portion 75 can be joined to the opposite end 74 by adhering, welding, or other methods. The float portion 75 can be formed of a relatively lightweight material separate from the components that provide the closure portion 71, fall prevention portion 72, insertion portion 73, and opposite end 74. The float portion 75 can be formed to include a material such as urethane or foamed plastic, such as polystyrene foam. In Figure 13 and other figures, the opposite end 74 is formed to protrude outward in the radial direction r to prevent the displacement member 70 from completely slipping out of the insertion hole 65 of the mounting member 60. However, if the floating portion 75 has a shape that does not pass through the insertion hole 65 when moving upward, the opposite end portion 74 does not need to be shaped to protrude outward in the radial direction r so as not to pass through the insertion hole 65.

[0310] Furthermore, the displacement member 70 may be provided with a circulation mechanism that allows the suction of gas while suppressing the suction of liquid during suction. As an example of the circulation mechanism, an insertion hole h1 (see FIGS. 13 and 14) of a few millimeters in size may be provided in the member that provides the blocking portion 71, the fall prevention portion 72, the insertion portion 73, and the opposite end portion 74, and countless very small holes may be provided in the floating portion 75 using foamed plastic or the like.

[0311] As shown in FIG. 13 , when the fall prevention portion 72 abuts against the abutment portion 63 of the attachment member 60, the displacement member 70 does not block the open end 53 of the inner portion 52 of the connecting member 50. This allows gas and other substances present in the internal space 12 of the container 10a to flow through the flow path of the connecting member 50 from the open end 53 of the connecting member 50 through the flow hole 64, as shown by the arrows in FIG. 12 . On the other hand, when the level of the body fluid present in the internal space 12 rises further from the state in which it is in contact with the float portion 75, the fall prevention portion 72 moves away from the abutment portion 63, the displacement member 70 moves upward, and the blocking portion 71 abuts against the open end 53 of the inner portion 52 of the connecting member 50. This blocks the open end 53. As a result, liquids such as body fluids and swelling substances W present in the internal space 12 cannot flow through the open end 53 of the connecting member 50. On the other hand, gas present in the internal space 12 can flow downstream through the tiny holes in the float portion 75 and the insertion hole h1 even when the blocking portion 71 is in contact with the open end 53 of the inner portion 52.

[0312] As described above, in this embodiment, the waste liquid treatment device 100 includes a container 10, an excrement treatment agent 20, a lid 30, and a partition member 40. The container 10 has an internal space 12 capable of containing bodily fluids contained in or excreted by a human being, and an opening 11 through which bodily fluids can be introduced into the internal space 12 by suction. The lid 30 can be attached to close the opening 11 of the container 10 and includes a connection portion 33 through which bodily fluids can flow into the internal space by suction. The partition member 40 is disposed in the internal space 12 and is configured to divide the internal space 12 into a first internal space 13 located proximal to the opening 11 and a second internal space 14 located distal to the opening 11 relative to the first internal space 13. The excrement treatment agent 20 is disposed in the second internal space 14 of the container 10 and is configured to convert the bodily fluid into a solid swelling substance w upon contact with the bodily fluid. The partition member 40 allows the body fluid flowing into the internal space 12 from the connection portion 33 to flow between the first internal space 13 and the second internal space 14. The partition member 40 is also configured to block the flow of the swelling substance w, which is generated when the body fluid that has flowed into the second internal space 14 comes into contact with the excrement treating agent 20, into the first internal space 13.

[0313] This configuration prevents substances generated when bodily fluids come into contact with the excrement treating agent 20 from clogging the connection part 34, which is the outlet-side flow path of the lid part 30. Furthermore, even if a specimen is collected from the body of a patient in a medical setting or the like and the collected specimen is accidentally collected in the internal space 12 of the container 10, the partition member 40 allows the swelling substance w to be placed in an internal space (second internal space 14) separate from the first internal space 13 where the specimen is present. This prevents the swelling substance w and the specimen from mixing, and allows the specimen to be relatively easily removed from the internal space 12 of the container 10.

[0314] The partition member 40 also includes a first member 41 that allows bodily fluid to flow between the second internal space 14 and the first internal space 13, and a second member 42 that is more rigid than the first member 41. This configuration makes it difficult for the partition member 40 to be deformed by the swelling substance w when the swelling substance w is produced in the second internal space 14. This prevents the swelling substance w from blocking the flow path of the connection part 34 of the lid part 30 when the excrement treating agent 20 swells due to contact with bodily fluid.

[0315] The cover 30 also includes a connection portion 34 as an outflow portion through which at least one of gas and body fluid discharged from the internal space 12 by suction can flow downstream. The second member 42 is disposed in the first internal space 13 when the partition member 40 is installed in the internal space 12, and includes a first wall portion p4 disposed between the connection portion 33 and the connection portion 34 and adjacent to the connection portion 34. This configuration can prevent or suppress the flow of body fluid flowing in from the connection portion 33 from flowing downstream from the connection portion 34 without moving from the first internal space 13 to the second internal space 14 through the hole p2.

[0316] The second member 42 also includes a covering portion p1 and a second wall portion p5. The covering portion p1 partially covers one side of the first member 41. The second wall portion p5 is disposed at or near the outer peripheral edge of the covering portion p1, adjacent to the connecting portion 33 in the first internal space 13 when the partition member 40 is installed in the internal space 12. This prevents bodily fluids that have flowed from the connecting portion 33 into the internal space 12 from reacting only with the excrement treatment agent 20 disposed below the connecting portion 33 in the second internal space 14, and promotes the flow of bodily fluids to the excrement treatment agent 20 disposed below the connecting portion 34.

[0317] The second members 42 are arranged in pairs to sandwich the first member 41. This configuration makes it possible to make the partition member 40 less likely to deform in the internal space 12 when body fluid comes into contact with the excrement treating agent 20 in the second internal space 14 and a swelling substance w is generated. This prevents the swelling substance w from blocking the flow path of the connecting portion 34 of the lid portion 30 when the excrement treating agent 20 swells due to contact with body fluid.

[0318] Furthermore, in this embodiment, the partition member 40 is provided with an engaging protrusion p3, and the lid 30 is provided with an engaging recess 35, so as to position the partition member 40 in the internal space 12 when the lid 30 is attached to the container 10. This configuration makes it difficult for the partition member 40 to shift from its intended position in the internal space 12, thereby preventing the swelling substance w from blocking the flow path of the connection part 34 of the lid 30 when the excrement treating agent 20 swells due to contact with bodily fluids.

[0319] The downstream waste liquid treatment device 100a includes a container 10a, a lid 30a attachable to the container 10a to close the opening 11 of the container 10a, an excrement treatment agent 20, and a displacement member 70. The container 10a has an internal space 12 and an opening 11. The lid 30a is attachable to the container 10a to close the opening 11 of the container 10a, and includes a connection 33 and a connection 34a that allows gas discharged from the internal space 12 by suction to flow downstream. The excrement treatment agent 20 is disposed in the internal space 12 of the container 10a and is configured to convert the body fluid into a swelling substance w upon contact with the body fluid. The displacement member 70 is configured to block the flow of the body fluid and the swelling substance w downstream when the swelling substance w generated upon contact of the excrement treatment agent 20 with the body fluid reaches a predetermined height in the internal space 12.

[0320] With this configuration, the swelling substance w can be collected in the internal space 12 of the downstream waste liquid treatment device 100a, and the body fluid and the swelling substance w can be prevented from flowing downstream.

[0321] The downstream waste liquid treatment device 100a also includes an attachment member 60. The attachment member 60 is attachable to the lid 30a and is configured to include an abutment portion 63 that holds the displacement member 70 near the connection portion 34a of the internal space 12 when the displacement member 70 does not block the flow of the body fluid and the swelling substance w. This allows the displacement member 70 to be placed on standby so that, when the body fluid level rises in the internal space 12 of the container 10a, the displacement member 70 can block the flow of the body fluid and the swelling substance w through the flow path of the connecting member 50 attached to the connection portion 34a.

[0322] The displacement member 70 also includes a blocking portion 71 and a fall prevention portion 72. The blocking portion 71 is configured to be able to at least partially block the flow path of the connecting member 50 attached to the connection portion 34a. The fall prevention portion 72 is able to abut against the abutting portion 63 of the attachment member 60, and this abutment holds the displacement member 70 at a position near the connection portion 34a in the internal space 12. This allows the displacement member 70 to wait in a position where it can obstruct the flow of the body fluid and the swelling substance w when body fluid flows into the internal space 12 of the container 10a and does not block the flow path of the connecting member 50 attached to the connection portion 34a.

[0323] The displacement member 70 is also configured to include a floating portion 75 that is provided at the lower end in the direction of gravity and that can float the displacement member 70 on the surface of the body fluid when in contact with the surface of the body fluid in the internal space 12. This makes it easier to move the displacement member 70 upward in response to a rise in the body fluid level, and allows the displacement member 70 to be moved to a position that covers the flow path of the connecting member 50 so that the body fluid and swelling substance w do not flow into the flow path of the connecting member 50 attached to the connection portion 34a.

[0324] Furthermore, the displacement member 70 can be provided with a flow mechanism that allows the suction of gas while suppressing the suction of liquid during suction. With this configuration, even when the blocking portion 71 blocks the open end 53 of the inner portion 52 of the connecting member 50, the gas or the like can be sucked in by a pump or the like arranged downstream.

[0325] The present invention is not limited to the above-described embodiment, and various modifications are possible within the scope of the claims. In Fig. 2 and other figures, two waste liquid treatment devices 100 and one downstream waste liquid treatment device 100a are provided. However, as long as the required body fluids, etc., can be treated in a medical setting or disaster site, the specific numbers of waste liquid treatment devices and downstream waste liquid treatment devices are not limited to those shown in Fig. 2 and other figures. Furthermore, as long as the required body fluids, etc., can be treated, it is possible to provide only one waste liquid treatment device 100 and not a downstream waste liquid treatment device 100a.

[0326] Fig. 15 is an exploded perspective view of a waste liquid treatment device 100b according to a modified example of Fig. 4, and Fig. 16 is an exploded perspective view of a downstream waste liquid treatment device 100c according to a modified example of Fig. 10. As described above, the excrement treatment agent 20 and the like are stored in the internal space 12 of the container 10 of the waste liquid treatment device 100 or the downstream waste liquid treatment device 100a, and when a swelling substance w is generated upon contact of a body fluid with the excrement treatment agent 20, the swelling substance w and the like present in the internal space 12 can be discarded together with the container 10. However, if the swelling substance w and the like can be disposed of, the container 10 does not need to be discarded together with the swelling substance w every time the swelling substance w is generated. In other words, a disposable bag 80 such as a plastic bag may be placed in the internal space 12 of the container 10 of the waste liquid treatment device 100b or the downstream waste liquid treatment device 100c, and the excrement treatment agent 20 may be placed inside the disposable bag 80 (see Figs. 15 and 16).

[0327] The above-mentioned vinyl bag, drawstring bag, or bag with a zipper can be used as the disposable bag 80. By configuring it in this manner, when the swelling substance w is produced, the disposable bag 80 can be discarded together with the swelling substance w, and at least one of the containers 10, 10a of the waste liquid treatment device and the downstream waste liquid treatment device can be reused.

[0328] In addition, the partition member 40 has been described above as including the first wall portion p4 and the second wall portion p5. However, as long as bodily fluid that has flowed into the internal space 12 from the connection portion 33 can circulate into the second internal space 14, the partition member 40 may be configured not to include the first wall portion p4 and the second wall portion p5, or to include only one of the first wall portion p4 and the second wall portion p5.

[0329] Furthermore, although it has been described that the displacement member 70 includes a floating portion 75, the displacement member does not have to include a floating portion 75 as long as it can come into contact with the liquid surface of the body fluid in the internal space 12 of the container 10a and move upward in response to the rise in the liquid surface.

[0330] 17 is a perspective view showing the configuration of a partition member 40d according to a modified example, FIG. 18 is an exploded perspective view of FIG. 17, FIG. 19 is a plan view of FIG. 17, and FIG. 20 is a perspective view showing a partition member 40e according to a modified example.

[0331] 8 and other figures, the partition member 40 has a first member 41 and a second member 42, and the first member 41 is configured to be disposed between the two second members 42. However, the specific form of the partition member is not limited to the above, as long as it allows the body fluid flowing into the internal space 12 from the connection portion 33 to circulate between the first internal space 13 and the second internal space 14 and prevents the swelling substance w generated in the second internal space 14 from circulating into the first internal space 13.

[0332] In addition to the above, the partition member 40d may be a first member 41d having a plurality of holes formed on a second member 42d, as shown in Fig. 17. The first member 41d has countless holes formed in a substantially circular shape.

[0333] As shown in FIG. 18 , the second member 42d includes a covering portion p1d, a hole p2d, and an engaging protrusion p3d. The covering portion p1d has an outer peripheral shape that is substantially the same as the horizontal cross-sectional shape of the container 10 when the container 10 is installed. The hole p2d can be provided with an inlet hole and an outlet hole in at least a portion of the first member 41d when the first member 41d is installed, allowing bodily fluid to flow from the first internal space 13 to the second internal space 14 (see FIG. 18 ). The engaging protrusion p3d has a configuration similar to the engaging protrusion p3 of the partition member 40. The portion of the partition member 40 corresponding to the first wall portion p4 can be installed on the first member 41d as a wall member 43d. The wall member 43d is positioned near the connecting portion 34 on the path along which bodily fluid flows in the internal space 12 between the connecting portion 33 and the connecting portion 34 of the lid portion 30. Like the first wall portion p4 of the partition member 40, the wall member 43d prevents or suppresses bodily fluids from flowing downstream from the first internal space 13 without passing through the second internal space 14.

[0334] Furthermore, although the partition member 40d is configured with the first member 41d, second member 42d, and wall member 43d each composed of separate parts, these may also be configured as a single part, as in the partition member 40e shown in Figure 20. In this case, instead of providing the hole p2d in the partition member 40d, the countless holes in the first member 41d can be used as the hole p2e. The covering portion p1e is a flat portion outside the hole p2e that does not have the hole p2e, and the engaging protrusion p3e and first wall portion p4e can be configured similarly to the engaging protrusion p3 and first wall portion p4d of the partition member 40d, respectively. The second wall portions p5e, p6e, and p7e include the second wall portion p5e, which is relatively large in size, and second wall portions p6e and p7e, which are smaller in size than the second wall portion p5e, are spaced apart in the circumferential direction, and are arranged in pairs. However, if bodily fluids can flow from the hole portion p2e to the second internal space 14 on the partition member 40, the second wall portions p6e and p7e do not need to be provided.

[0335] FIG. 21 shows a modified example of FIG. 13 , and FIG. 22 shows a modified example of FIG. 14 . In FIGS. 13 and 14 , the displacement member 70 of the downstream waste liquid treatment tool 100 a includes a blocking portion 71, a fall prevention portion 72, an insertion portion 73, a reverse end portion 74, and a floating portion 75. The blocking portion 71 of the displacement member 70 is provided at the upper tip of the displacement member 70, but this is not limited thereto. The blocking portion 71 d can be provided on the distal end surface of the floating portion 75 d. The fall prevention portion 72 of the displacement member 70 is provided on the opposite side of the blocking portion 71, but the fall prevention portion 72 d of the displacement member 70 d can be a stepped end surface made of plastic or the like. The insertion portion 73 d can be a stepped cylindrical vertical wall. The reverse end portion 74 d can be a cylindrical end that contacts the floating portion 75. The floating portion 75d is integrally joined to the cylindrical shape including the fall prevention portion 72d and the opposite end portion 74d, and can be made of a foam material such as urethane.

[0336] Fig. 23 is a perspective view showing a modified example of Fig. 2, Fig. 24 is an exploded perspective view showing a capture assembly 80d, and Fig. 25 is a view showing the inside of the capture assembly 80d. The waste liquid treatment tools 100 can be connected to each other by a connecting member 50, but a capture assembly 80d (corresponding to the capture part) may be attached to the connection part 33 of the waste liquid treatment tool 100 located most upstream of the waste liquid treatment tool 100 shown in Fig. 2 instead of the connecting member 50 (see Fig. 23).

[0337] The capture assembly 80d includes a lid portion 81, a container 85, and a compartment portion 91 as shown in FIG.

[0338] The lid portion 81 includes an attachment portion 82, an upper portion 83, and a side portion 84. The upper portion 83 is configured to close an opening 88 of a container 85. The side portion 84 is provided to be continuous with the upper portion 83 at the outer periphery of the upper portion 83 and is configured to be connectable to the container 85. The inside of the side portion 84 can be mated with the container 85 or can be connected to the container 85 by providing a threaded or grooved shape. The attachment portion 82 can be connected to a tubular member T or the like, and has holes that allow the passage of body fluids, polyps, etc. discharged from the patient.

[0339] The container 85 includes a wall surface 86, a step portion 87, an opening 88, and a discharge portion 89. The wall surface 86 is configured to form the side wall and bottom wall of the container 85. The step portion 87 is provided at a middle position on the inner side wall of the wall surface 86 so that a partition portion 91 (described later) can be installed. The opening portion 88 is a portion that is covered by the lid portion 81 and is provided at the top of the container 85. The discharge portion 89 is provided at the bottom of the container 85 so that bodily fluid that flows in from the opening portion 88 can circulate downstream.

[0340] The partitioning unit 91 includes a filter 92, partitions 93, and supports 94. The filter 92 has numerous holes for separating solid components, such as polyps, contained in the body fluid that flows in through the attachment unit 82 from the body fluid. The partitions 93 are provided at predetermined angular intervals on the upper part of the filter 92. The partitions 93 are shaped to divide the upper part of the filter 92 circumferentially in a plan view, so as to provide multiple locations for disposing of solid components separated from the body fluid on the filter 92. The partitioning unit 91 is configured to be rotatable relative to the container 85. By rotating and changing the position of the partitions 93 relative to the attachment unit 82, for example, solid components can be captured on the filter 92 separately for each patient. The supports 94 are provided approximately at the center of the partitions 93 so as to be integrated with the multiple partitions 93. This configuration allows solid components, such as polyps, to be removed (separated) relatively quickly from the waste liquid to be treated.

[0341] The present invention encompasses the following aspects and configurations.

[0342] 1. A waste liquid treatment device comprising: a container having an internal space capable of containing body fluid contained in or excreted from a human being, and an opening through which the body fluid can be introduced into the internal space by suction; a lid attachable to the container to close the opening of the container and having an inlet through which the body fluid can flow into the internal space by suction; a partition member disposed in the internal space and dividing the internal space into a first internal space proximal to the opening and a second internal space located distal to the opening relative to the first internal space; and an excrement treatment agent disposed in the second internal space of the container and which turns the body fluid into a solid swelling substance upon contact with the body fluid, wherein the partition member allows the body fluid flowing from the inlet into the internal space to flow between the first internal space and the second internal space, and can block the flow of the swelling substance produced when the body fluid that has flowed into the second internal space comes into contact with the excrement treatment agent into the first internal space.

[0343] 2. The waste liquid treatment device according to claim 1, wherein the partition member includes a first member that allows the body fluid to flow between the second internal space and the first internal space, and a second member that is more rigid than the first member.

[0344] 3. The waste liquid treatment tool according to claim 2, wherein the lid portion includes an outlet portion that allows at least one of the gas and the body fluid discharged from the internal space by the suction to circulate downstream, and the second member includes a first wall portion that is disposed in the first internal space when the partition member is installed in the internal space, and that is disposed between the inlet portion and the outlet portion and adjacent to the outlet portion.

[0345] 4. The waste liquid treatment tool according to claim 2 or 3, wherein the second member comprises a covering portion that partially covers one side of the first member, and a second wall portion that is disposed at or near the outer circumferential edge of the covering portion and adjacent to the inlet portion in the first internal space when the partition member is installed in the internal space.

[0346] 5. The waste liquid treatment tool according to any one of 1 to 4 above, wherein the inlet section can be fitted with a capture section including a filter capable of separating solid components contained in the body fluid from the body fluid.

[0347] 6. The waste liquid treatment device according to any one of 1 to 5 above, wherein a convex portion is provided on one of the lid portion and the partition member, and a concave portion engageable with the convex portion is provided on the other, so as to position the partition member in the internal space when the lid portion is attached to the container.

[0348] 7. A downstream waste liquid treatment device connectable to any of the waste liquid treatment devices described above in any one of 1 to 6 via a tubular member, comprising: a second container provided with the internal space and the opening; a second lid attachable to the second container so as to close the opening of the second container and including the inlet section and a second outlet section through which gas discharged from the internal space by the suction can circulate downstream; the excrement treatment agent disposed in the internal space of the second container and which turns the body fluid into the swelling substance upon contact with the body fluid; and a displacement member which blocks the flow of the body fluid and the swelling substance downstream when the swelling substance produced by contact of the excrement treatment agent with the body fluid reaches a predetermined height in the internal space.

[0349] 8. The downstream waste liquid treatment device according to claim 7, further comprising an attachment member that can be attached to the second lid portion and that has an abutment portion that holds the displacement member in the vicinity of the second outflow portion of the internal space when the displacement member does not block the flow of the body fluid and the swelling substance.

[0350] 9. The downstream waste liquid treatment device according to claim 8, wherein the displacement member includes a blocking portion capable of at least partially blocking the flow path of the second outflow portion, and a fall prevention portion capable of abutting against the abutting portion of the attachment member and holding the displacement member at a position near the second outflow portion in the internal space by the abutment.

[0351] 10. The downstream waste liquid treatment device according to any one of claims 7 to 9, wherein the displacement member is provided at a lower end in the direction of gravity and includes a floating portion that can float the displacement member on the liquid surface when in contact with the liquid surface of the body fluid in the internal space.

[0352] 11. The downstream waste liquid treatment tool according to any one of the above items 7 to 10, wherein the displacement member is provided with a flow mechanism that allows the suction of gas while suppressing the suction of liquid during the suction.

[0353] This concludes the description of the second invention.

[0354] This application is based on Japanese Patent Application Nos. 2022-173428 and 2022-173431, filed on October 28, 2022, the disclosures of which are incorporated herein by reference in their entireties.

[0355] REFERENCE SIGNS LIST 10 Container, 10a Container (second container), 11 Opening, 12 Internal space, 13 First internal space, 14 Second internal space, 20 Excrement treatment agent, 30 Lid portion, 30a Lid portion (second lid portion), 33 Connection portion (inlet portion), 34 Connection portion (outlet portion), 34a Connection portion (second outlet portion), 35 Engagement recess, 40 Partition member, 41 First member, 42 Second member, 50 Linking member, 60 Mounting member, 63 Contact portion, 70 Displacement member, 71 Closing portion, 72 Fall prevention portion, 75 Floating portion, 80 Capture assembly (capture portion), 92 Filter, 100 Waste liquid treatment device, 100a Downstream waste liquid treatment device, h1 Insertion hole (distribution mechanism), p1 Covering portion, p3 engaging convex portion, p4 first wall portion, p5 second wall portion, T tubular member, w swelling substance.

Claims

1. A treatment agent for treating wastewater, comprising hydrated lime and pepper.

2. The treatment of claim 1, wherein the pepper is not in the form of a piperine extract.

3. The treatment agent according to claim 1, which comprises a water-absorbing polymer.

4. The treatment agent according to claim 1, wherein the content (mass%) of the slaked lime is 0.1 to 40 mass%, and the content (mass%) of the pepper is 0.05 to 30 mass%.

5. The treatment according to claim 1, which contains zinc oxide.

6. The treatment agent according to claim 5, which contains at least one selected from the group consisting of lignin, bentonite and zeolite.

7. The treatment agent according to claim 6, further comprising humic acid.

8. The treatment agent according to claim 1, wherein the waste liquid comprises excrement, blood, vomit or bodily fluids discharged from humans or animals.

9. The treatment agent according to claim 1, wherein the waste liquid contains at least one of indole and skatole as a malodorous component.

10. The treatment agent according to claim 1, which is used to suppress or inhibit spore germination or proliferation of spore-forming bacteria.

11. The treatment agent according to claim 10, wherein the spore-forming bacterium is Clostridioides difficile.

12. A method for suppressing or inhibiting spore germination or proliferation of spore-forming bacteria, which comprises contacting a waste liquid with the treating agent according to any one of claims 1 to 11.

13. A waste liquid treatment device comprising: a container having an internal space capable of containing body fluids contained in or excreted from humans, and an opening through which the body fluid can be introduced into the internal space by suction; a lid that can be attached to the container to close the opening of the container and has an inlet that allows the body fluid to flow into the internal space by suction; a partition member that is disposed in the internal space and divides the internal space into a first internal space proximal to the opening and a second internal space that is located more distal to the opening than the first internal space; and an excrement treatment agent that is disposed in the second internal space of the container and turns the body fluid into a solid swelling substance upon contact with the body fluid, wherein the partition member allows the body fluid that flows into the internal space from the inlet to flow between the first internal space and the second internal space, and can block the flow of the swelling substance produced when the body fluid that has flowed into the second internal space comes into contact with the excrement treatment agent into the first internal space.

14. A waste liquid treatment device as described in claim 13, wherein the partition member comprises a first member that allows the body fluid to flow between the second internal space and the first internal space, and a second member that is more rigid than the first member.

15. A waste liquid treatment device as described in claim 14, wherein the lid portion has an outlet portion that allows at least one of the gas and the body fluid discharged from the internal space by the suction to flow downstream, and the second member has a first wall portion that is positioned in the first internal space when the partition member is installed in the internal space, and is positioned between the inlet portion and the outlet portion and adjacent to the outlet portion.

16. A waste liquid treatment device as described in claim 14, wherein the second member comprises a covering portion that partially covers one side of the first member, and a second wall portion that is positioned adjacent to the inlet portion in the first internal space at or near the outer peripheral edge of the covering portion when the partition member is installed in the internal space.

17. A waste liquid treatment device according to claim 13, wherein the inlet section can be fitted with a capture section including a filter capable of separating solid components contained in the body fluid from the body fluid.

18. A waste liquid treatment device as described in claim 13, wherein a convex portion is provided on one of the lid portion and the partition member, and a concave portion that can engage with the convex portion is provided on the other, so as to position the partition member in the internal space when the lid portion is attached to the container.

19. A downstream waste liquid treatment device connectable to the waste liquid treatment device described in claim 13 via a tubular member, comprising: a second container provided with the internal space and the opening; a second lid attachable to the second container so as to close the opening of the second container and comprising the inlet portion and a second outlet portion through which gas discharged from the internal space by the suction can circulate downstream; the excrement treatment agent disposed in the internal space of the second container and which turns the body fluid into the swelling substance upon contact with the body fluid; and a displacement member which blocks the flow of the body fluid and the swelling substance downstream when the swelling substance produced by contact of the excrement treatment agent with the body fluid reaches a predetermined height in the internal space.

20. A downstream waste liquid treatment device as described in claim 19, comprising an attachment member that can be attached to the second lid portion and has an abutment portion that holds the displacement member near the second outlet portion of the internal space when the displacement member does not block the flow of the body fluid and the swelling substance.

21. A downstream waste liquid treatment device as described in claim 21, wherein the displacement member comprises a blocking portion capable of at least partially blocking the flow path of the second outlet portion, and a fall prevention portion capable of abutting against the abutment portion of the mounting member and, by abutment, holding the displacement member at a position near the second outlet portion in the internal space.

22. A downstream waste liquid treatment device as described in claim 19, wherein the displacement member is provided at its lower end in the direction of gravity and has a floating portion that can float the displacement member on the liquid surface when in contact with the liquid surface of the body fluid in the internal space.

23. A downstream waste liquid treatment tool according to claim 19, wherein the displacement member is provided with a flow mechanism that suppresses the suction of liquid while allowing the suction of gas during the suction.